Omnicell (OMCL) 10-K 27 Feb 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2017	Feb. 21, 2018	Jun. 30, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	OMNICELL, Inc
Entity Central Index Key	926,326
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Public Float, non-affiliates			$ 1.6
Entity Common Stock, Shares Outstanding		38,783,241
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 32,424	$ 54,488
Accounts receivable, net of allowances of $5,738 and $4,796, respectively	189,227	150,303
Inventories	96,137	69,297
Prepaid expenses	36,060	28,646
Other current assets	13,273	12,674
Total current assets	367,121	315,408
Property and equipment, net	42,595	42,011
Long-term investment in sales-type leases, net	15,435	20,585
Goodwill	337,751	327,724
Intangible assets, net	168,107	190,283
Long-term deferred tax assets	9,454	4,041
Other long-term assets	39,841	35,051
Total assets	980,304	935,103
Current liabilities:
Accounts payable	48,290	27,069
Accrued compensation	27,241	26,722
Accrued liabilities	35,693	31,195
Long-term debt, current portion, net	15,208	8,410
Deferred revenue, net	86,104	87,516
Total current liabilities	212,536	180,912
Long-term deferred revenue	17,244	17,051
Long-term deferred tax liabilities	28,579	51,592
Other long-term liabilities	9,829	8,210
Long-term debt, net	194,917	245,731
Total liabilities	463,105	503,496
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued	0	0
Common stock, $0.001 par value, 100,000 shares authorized; 47,577 and 45,778 shares issued; 38,432 and 36,633 shares outstanding, respectively	48	46
Treasury stock at cost, 9,145 shares outstanding, respectively	(185,074)	(185,074)
Additional paid-in capital	585,755	525,758
Retained earnings	122,583	100,396
Accumulated other comprehensive income (loss)	(6,113)	(9,519)
Total stockholders’ equity	517,199	431,607
Total liabilities and stockholders’ equity	$ 980,304	$ 935,103

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Allowances	$ 5,738	$ 4,796
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	47,577,000	45,778,000
Common stock, shares outstanding	38,432,000	36,633,000
Treasury stock, shares outstanding	9,145,000	9,145,000
Preferred stock, shares issued	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues:
Product	$ 506,209	$ 517,944	$ 388,397
Services and other revenues	209,956	174,679	96,162
Total revenues	716,165	692,623	484,559
Cost of revenues:
Cost of product revenues	304,842	302,437	198,418
Cost of services and other revenues	89,235	76,386	38,211
Total cost of revenues	394,077	378,823	236,629
Gross profit	322,088	313,800	247,930
Operating expenses:
Research and development	66,022	57,799	35,160
Selling, general and administrative	250,312	249,520	167,581
Gain on business combination	0	0	(3,443)
Total operating expenses	316,334	307,319	199,298
Income from operations	5,754	6,481	48,632
Interest and other income (expense), net	(6,633)	(8,429)	(2,388)
Income (loss) before provision for income taxes	(879)	(1,948)	46,244
Provision for (benefit from) income taxes	(21,484)	(2,551)	15,484
Net income	$ 20,605	$ 603	$ 30,760
Net income per share:
Basic (in dollars per share)	$ 0.55	$ 0.02	$ 0.86
Diluted (in dollars per share)	$ 0.53	$ 0.02	$ 0.84
Weighted-average shares:
Basic (in shares)	37,483	36,156	35,857
Diluted (in shares)	38,712	36,864	36,718

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Statement of Comprehensive Income [Abstract]
Net income	$ 20,605	$ 603	$ 30,760
Other comprehensive income (loss), net of reclassification adjustments:
Unrealized gain (loss) on interest rate swap contracts, net of tax	(404)	1,245	0
Foreign currency translation adjustments	3,810	(8,034)	(1,369)
Other comprehensive gain (loss)	3,406	(6,789)	(1,369)
Comprehensive income (loss)	$ 24,011	$ (6,186)	$ 29,391

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Treasury Stock	Additional Paid-In Capital	Accumulated Earnings (Deficit)	Accumulated Other Comprehensive Income (Loss)
Common Stock, Beginning of period (in shares) at Dec. 31, 2014		43,537,000
Stockholders' Equity, Beginning of period at Dec. 31, 2014	$ 390,098	$ 43	$ 135,053	$ 457,436	$ 69,033	$ (1,361)
Treasury Stock, Beginning of period (in shares) at Dec. 31, 2014			7,721,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	30,760				30,760
Other comprehensive income (loss)	(1,369)					(1,369)
Stock repurchases (in shares)			(1,424,000)
Stock repurchases	(50,021)		$ (50,021)
Share-based compensation	14,921			14,921
Issuance of common stock under employee stock plans (in shares)		1,202,000
Issuance of common stock under employee stock plans	17,091	$ 2		17,089
Tax payments related to restricted stock units	(3,627)			(3,627)
Income tax benefits from employee stock plans	4,535			4,535
Common Stock, End of period (in shares) at Dec. 31, 2015		44,739,000
Stockholders' Equity, End of period at Dec. 31, 2015	402,388	$ 45	$ 185,074	490,354	99,793	(2,730)
Treasury Stock, End of period (in shares) at Dec. 31, 2015			9,145,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	603				603
Other comprehensive income (loss)	$ (6,789)					(6,789)
Stock repurchases (in shares)	0
Share-based compensation	$ 19,500			19,500
Issuance of common stock under employee stock plans (in shares)		1,039,000
Issuance of common stock under employee stock plans	17,692	$ 1		17,691
Tax payments related to restricted stock units	(3,490)			(3,490)
Income tax benefits from employee stock plans	1,703			1,703
Common Stock, End of period (in shares) at Dec. 31, 2016		45,778,000
Stockholders' Equity, End of period at Dec. 31, 2016	$ 431,607	$ 46	$ 185,074	525,758	100,396	(9,519)
Treasury Stock, End of period (in shares) at Dec. 31, 2016	9,145,000		9,145,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	$ 20,605
Other comprehensive income (loss)	3,406					3,406
At the market offering, net of offering costs (in shares)		294,000
At the market equity offering, net of costs	$ 13,900			13,900
Stock repurchases (in shares)	0
Share-based compensation	$ 21,857			21,857
Issuance of common stock under employee stock plans (in shares)		1,505,000
Issuance of common stock under employee stock plans	30,123	$ 2		30,121
Tax payments related to restricted stock units	(5,892)			(5,892)
Income tax benefits from employee stock plans	11			11
Common Stock, End of period (in shares) at Dec. 31, 2017		47,577,000
Stockholders' Equity, End of period at Dec. 31, 2017	$ 517,199	$ 48	$ 185,074	$ 585,755	122,583	$ (6,113)
Treasury Stock, End of period (in shares) at Dec. 31, 2017	9,145,000		9,145,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative effect of a change in accounting principle related to stock-based compensation	$ 1,582				$ 1,582

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Operating Activities
Net income	$ 20,605	$ 603	$ 30,760
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	51,511	58,362	25,639
Loss on disposal of fixed assets	512	35	238
Gain on business combinations	0	0	(3,443)
Gain related to contingent liability	0	(600)	0
Share-based compensation expense	21,857	19,500	14,921
Income tax benefits from employee stock plans	11	1,703	4,535
Deferred income taxes	(26,844)	(10,882)	(1,092)
Amortization of debt financing fees	1,590	1,590	0
Changes in operating assets and liabilities, net of business acquisitions:
Accounts receivable	(39,068)	8,047	(17,941)
Inventories	(26,840)	(3,362)	(10,032)
Prepaid expenses	(7,414)	(4,321)	4,049
Other current assets	(2,074)	(1,093)	638
Investment in sales-type leases	6,625	(9,639)	(4,661)
Other long-term assets	(98)	2,043	496
Accounts payable	19,709	(4,963)	(2,841)
Accrued compensation	519	(2,052)	(2,032)
Accrued liabilities	4,383	(3,287)	5,456
Deferred revenue	(1,219)	4,480	(5,521)
Other long-term liabilities	1,069	(6,264)	(683)
Net cash provided by operating activities	24,834	49,900	38,486
Investing Activities
Purchase of intangible assets, intellectual property and patents	(160)	(1,372)	(415)
Software development for external use	(15,040)	(14,348)	(12,132)
Purchases of property and equipment	(15,341)	(13,445)	(7,542)
Business acquisitions, net of cash acquired	(4,446)	(312,158)	(25,507)
Net cash used in investing activities	(34,987)	(341,323)	(45,596)
Financing Activities
Proceeds from debt, net	56,894	287,051	0
Repayment of debt and revolving credit facility	(102,500)	(34,500)	0
Payment for contingent consideration	(2,400)	(3,000)	0
Proceeds from issuances under stock-based compensation plans	30,121	17,691	17,091
Employees' taxes paid related to restricted stock units	(5,892)	(3,490)	(3,627)
At the market offering, net of offering costs	13,900	0	0
Common stock repurchases	0	0	(50,021)
Net cash provided by (used in) financing activities	(9,877)	263,752	(36,557)
Effect of exchange rate changes on cash and cash equivalents	(2,034)	(58)	(4)
Net increase (decrease) in cash and cash equivalents	(22,064)	(27,729)	(43,671)
Cash and cash equivalents at beginning of period	54,488	82,217	125,888
Cash and cash equivalents at end of period	32,424	54,488	82,217
Supplemental cash flow information
Cash paid for interest	6,550	5,344	76
Cash paid for taxes, net of refunds	7,780	11,091	11,871
Supplemental disclosure of non-cash investing activities
Non-cash activity business acquisition	3,400	0	7,386
Unpaid property and equipment purchases	$ 1,691	$ 246	$ 1,398

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	Organization and Summary of Significant Accounting Policies Business Omnicell, Inc. was incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. The Company's major products are automated medication, supply control systems and medication adherence solutions which are sold in its principal market, which is the healthcare industry. The Company's market is primarily located in the United States and Europe. "Omnicell" or the "Company" refer to Omnicell, Inc. and its subsidiaries. Principles of consolidation The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. GAAP and include all adjustments necessary for the fair presentation of the Company's consolidated financial position, results of operations and cash flows for the periods presented. The Consolidated Financial Statements include the Company's accounts as well as those of its wholly owned subsidiaries after the elimination of intercompany balances and transactions. On April 12, 2017, the Company completed its acquisition of Dixie Drawl, LLC d/b/a InPharmics ("InPharmics"). On December 8, 2016, the Company completed its acquisition of Ateb, Inc. and Ateb Canada Ltd. (together, “Ateb”). On January 5, 2016, the Company completed its acquisition of Aesynt Holding Cooperatief U.A. (“Aesynt”). On April 30, 2015, the Company acquired the remaining 85% of the issued and outstanding ordinary shares of Avantec Healthcare Limited (“Avantec”) not already held by Omnicell. On April 21, 2015, the Company completed its acquisition of Mach4 Automatisierungstechnik GmbH (“Mach4”). The consolidated financial statements include the results of operations of these recently acquired companies, commencing as of their respective acquisition dates. The significant accounting policies of the acquired businesses have been aligned to conform to the accounting policies of Omnicell. Certain prior year amounts in the Consolidated Statement of Cash Flows have been reclassified to conform to the 2017 presentation with the adoption of Accounting Standards Update ("ASU") 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting . Additionally, see "Recently adopted authoritative guidance" section below for the effects of adoption of ASU 2016-09. Use of estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company's Consolidated Financial Statements and accompanying Notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. The Company's critical accounting policies are those that affect its financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, allowance for doubtful accounts and notes receivable from investment in sales-type leases, inventory valuation, capitalized software development costs, valuation and impairment of goodwill, purchased intangibles and long-lived assets, fair value of assets acquired and liabilities assumed in business combination, share-based compensation and accounting for income taxes. Segment reporting The Company's Chief Operating Decision Maker ("CODM") is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company's segments using information about its revenues, gross profit, and income from operations. Such evaluation excludes general corporate-level costs that are not specific to either of the reportable segments and are managed separately at the corporate level. Corporate-level costs include expenses related to executive management, finance and accounting, human resources, legal, training and development, and certain administrative expenses. See Note 14, Segment and Geographical Information, for additional information on segment reporting. The operating results of the recently acquired InPharmics, Aesynt, Mach4 and Avantec businesses are included in the Company's Automation and Analytics reportable segment. The operating results of the recently acquired Ateb business is included in the Medication Adherence reportable segment. Foreign currency translation and remeasurement Most of the Company's foreign subsidiaries use the local currency of their respective countries as their functional currency. The Company translates the assets and liabilities of such non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Revenue and expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recorded as foreign currency translation adjustments and included in accumulated other comprehensive income (loss) in stockholders’ equity. The Company’s foreign subsidiaries that use the U.S. dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the end of each period, and non-monetary assets and liabilities at historical rates. Gains and losses from such foreign currency remeasurement are recorded in interest and other income (expense). Revenue recognition The Company earns revenues from sales of its medication and medical and surgical supply automation systems along with consumables and related services, which are sold in the healthcare industry, its principal market. Revenues are reported net of discounts and rebates provided to its customers. The Company's customer arrangements typically include one or more of the following deliverables: Products. Software-enabled equipment that manages and regulates the storage and dispensing of pharmaceuticals, consumable blister cards and packaging equipment and other medical supplies. Software. Additional software applications that enable incremental functionality of its equipment. Installation. Installation of equipment as integrated systems at customers' sites. Post-installation technical support. Phone support, on-site service, parts and access to unspecified software upgrades and enhancements, if and when available. Professional services. Other customer services, such as training and consulting. The Company recognizes revenue when the earnings process is complete, based upon its evaluation of whether the following four criteria have been met: Persuasive evidence of an arrangement exists. The Company uses signed customer contracts and signed customer purchase orders as evidence of an arrangement for leases and sales. For service engagements, the Company uses a signed services agreement and a statement of work to evidence an arrangement. Delivery has occurred. Equipment and embedded software product delivery is deemed to occur upon successful installation and receipt of a signed and dated customer confirmation of installation letter, providing evidence that the Company has delivered what a customer ordered. In instances of a customer self-installation, product delivery is deemed to have occurred upon receipt of a signed and dated customer confirmation letter. If a sale does not require installation, the Company recognizes revenue on delivery of products to the customer, including transfer of title and risk of loss, assuming all other revenue criteria are met. For existing distributors, where installation of equipment training has been previously provided and the distributor is certified to install the Company's equipment at the end-user customer facility, the Company recognizes revenue from sales of products to the distributor upon shipment assuming all other revenue criteria are met, net of allowance for rights of return or refund. For new distributors, where the Company has not provided installation of equipment training, revenue on the sales of products to the distributor is deferred until the distributor has completed the Distributor Training Program and has been certified to install the Company's equipment at the end-user facility. For the sale of consumable blister cards, the Company recognizes revenue when title and risk of loss of the products shipped have transferred to the customer, which usually occurs upon shipment from the Company's facilities. Assuming all other revenue criteria are met, the Company recognizes revenue for support services ratably over the related support services contract period. The Company recognizes revenue on training and professional services as they are performed. Fee is fixed or determinable. The Company assesses whether a fee is fixed or determinable at the outset of the arrangement based on the payment terms associated with the transaction. The Company has established a history of collecting under the original contract without providing concessions on payments, products or services. Collection is probable. The Company assesses the probability of collecting from each customer at the outset of the arrangement based on a number of factors, including the customer's payment history and its current creditworthiness. If, in the Company's judgment, collection of a fee is not probable, the Company defers revenue recognition until the uncertainty is removed, which generally means revenue is recognized upon the Company's receipt of cash payment assuming all other revenue criteria are met. The Company's historical experience has been that collection from its customers is generally probable. In arrangements with multiple deliverables, assuming all other revenue criteria are met, the Company recognizes revenue for individual delivered items if they have value to the customer on a standalone basis. The Company allocates arrangement consideration at the inception of the arrangement to all deliverables using the relative selling price method. This method requires the Company to determine the selling price at which each deliverable could be sold if it were sold regularly on a standalone basis. When available, the Company uses vendor-specific objective evidence ("VSOE") of the selling price. VSOE represents the price charged for a deliverable when it is sold separately, or for a deliverable not yet being sold separately, the price established by management with the relevant authority. The Company considers VSOE to exist when approximately 80% or more of its standalone sales of an item are priced within a reasonably narrow pricing range (plus or minus 15% of the median rates). The Company has established VSOE of the selling price for its post-installation technical support services and professional services. When VSOE of selling price is not available, third-party evidence ("TPE") of selling price for similar products and services is acceptable; however, the Company's offerings and market strategy differ from those of its competitors, such that it cannot obtain sufficient comparable information about third parties' prices. If neither VSOE nor TPE are available, the Company uses its best estimates of selling prices ("BESP"). The Company determines BESP considering factors such as market conditions, sales channels, internal costs and product margin objectives and pricing practices. The Company regularly reviews and updates its VSOE and BESP information. The relative selling price method allocates total arrangement consideration proportionally to each deliverable on the basis of its estimated selling price. In addition, the amount recognized for any delivered items cannot exceed that which is not contingent upon delivery of any remaining items in the arrangement. The Company also uses the residual method to allocate revenue between the software products that enable incremental equipment functionality, and thus are not deemed to deliver its essential functionality, and the related post-installation technical support, as these products and services continue to be accounted for under software revenue recognition rules. Under the residual method, the amount allocated to the undelivered elements equals VSOE of fair value of these elements. Any remaining amounts are attributed to the delivered items and are recognized when those items are delivered. A portion of the Company's sales are made through multi-year lease agreements. Under sales-type leases, the Company recognizes revenue for its hardware and software products net of lease execution costs such as post-installation product maintenance and technical support, at the net present value of the lease payment stream once its installation obligations have been met. The Company optimizes cash flows by selling a majority of its non-U.S. government leases to third-party leasing finance companies on a non-recourse basis. The Company has no obligation to the leasing company once the lease has been sold. Some of the Company's sales-type leases, mostly those relating to U.S. government hospitals which comprise approximately 33% of the lease receivable balance, are retained in-house. Interest income in these leases is recognized in product revenue using the effective interest method. The Company will adopt the ASU 2014-09, Revenue from Contracts with Customers, effective January 1, 2018. Please refer to “Recently issued authoritative guidance” which is included in Note 1 of this report. Financial Instruments For assets and liabilities measured at fair value, the amounts are based on an expected exit price representing the amount that would be received from the sale of an asset or paid to transfer a liability in a transaction between market participants. The fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs used in valuation techniques are assigned a hierarchical level. The following methods were used to estimate the fair value of each class of financial instruments for which it is practical to estimate that value: Cash and Cash Equivalents and Fair Value of Financial Instruments. The Company classifies investments as cash equivalents if their original or remaining contractual maturity is three months or less at the date of purchase. Cash equivalents are carried at amounts that approximate fair value due to the short period of time to maturity. The Company's cash balances are maintained in demand deposit accounts with financial institutions of high credit quality. The Company continuously monitors the credit worthiness of the financial institutions in which it invests. The Company has not experienced any credit losses from its cash investments. Foreign currency forward contracts. The Company enters into foreign currency forward contracts to protect its business from the risk that exchange rates may affect the eventual cash flows resulting from intercompany transactions between Omnicell and its foreign subsidiaries. These transactions primarily arise as a result of products manufactured in the United States ("U.S") and sold to foreign subsidiaries in U.S. dollars rather than the subsidiaries' functional currencies. These forward contracts are considered to be financial derivative instruments and are recorded at fair value. Changes in fair values of these financial derivative instruments are either recognized in other comprehensive income or net income depending on whether the derivative has been designated and qualifies as a hedging instrument. Interest rate swap agreements. During 2016, the Company entered into an interest rate swap agreement. The interest rate swap agreement, at its inception, qualified for and were designated as cash flow hedging instrument. In accordance with the Derivatives and Hedging Topic of the Accounting Standards Codification, the Company records its interest rate swaps on its consolidated balance sheet at fair value. The effective portion of changes in fair value are recorded in accumulated other comprehensive loss and are subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings. Any ineffective portion is recognized in earnings. Both at inception and on a quarterly basis, the Company performs an effectiveness test. For further information regarding these interest rate swap agreements, please refer to Note 4, Cash and Cash Equivalents and Fair Value of Financial Instruments . Debt. The Company has entered into a Credit Agreement which provides for (a) a five -year revolving credit facility and (b) a five -year term loan facility (Facilities). The amount borrowed under these facilities is recorded at its carrying value at December 31, 2017 . The fair value at December 31, 2017 approximates the carrying value. Allowance for doubtful accounts and notes receivables from investment in sales-types leases The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. The Company records a specific allowance based on an analysis of individual past-due balances. Additionally, based on historical write-offs and the Company's collection experience, the Company records an additional allowance based on a percentage of outstanding receivables. The Company performs credit evaluations of its customers' financial condition. These evaluations require significant judgment and are based on a variety of factors including, but not limited to, current economic trends, payment history and a financial review of the customer. Actual collection losses may differ from management's estimates, and such differences could be material to the Company's financial position and results of operations. There were no customers that accounted for more than 10% of the Company’s accounts receivable balance as of December 31, 2017 and December 31, 2016 . The retained in-house leases discussed above are considered financing receivables. The Company's credit policies and its evaluation of credit risk and write-off policies are applied alike to trade receivables and the net investment in sales-type leases. For both, an account is generally past due after thirty days. The financing receivables also have customer-specific reserves for accounts identified for specific impairment and a non-specific reserve applied to the remaining population, based on factors such as current trends, the length of time the receivables are past due and historical collection experience. The retained in-house leases are not stratified by portfolio or class. Sales of accounts receivable The Company records the sale of its accounts receivables as in accordance with accounting guidance for transfers and servicing of financial assets. The Company transferred non-recourse accounts receivable totaling $40.0 million , $28.7 million and $38.6 million during fiscal year 2017 , 2016 , and 2015 , respectively, which approximated fair value, to leasing companies on a non-recourse basis. Accounts receivable balance included approximately $0.1 million , $0.2 million and $0.8 million due from third-party leasing companies for transferred non-recourse accounts receivable as of December 31, 2017 , December 31, 2016 and December 31, 2015 , respectively. Inventory Inventories are stated at the lower of cost, computed using the first-in, first-out method, and net realizable value. Inbound shipping costs are included in cost of inventory. The Company regularly monitors inventory quantities on hand and records write-downs for excess and obsolete inventories based on the Company's estimate of demand for its products, potential obsolescence of technology, product life cycles, and whether pricing trends or forecasts indicate that the carrying value of inventory exceeds its estimated selling price. These factors are impacted by market and economic conditions, technology changes, and new product introductions and require estimates that may include elements that are uncertain. Actual demand may differ from forecasted demand and may have a material effect on gross margins. If inventory is written down, a new cost basis is established that cannot be increased in future periods. Shipments from suppliers or contract manufacturers before the Company receives them are recorded as in-transit inventory when title and the significant risks and rewards of ownership have passed to the Company. The Company has a supply agreement with one primary supplier for construction and supply of several sub-assemblies and inventory management of sub-assemblies used in our hardware products. There are no minimum purchase requirements. The contract with the Company's supplier may be terminated by either the supplier or by the Company without cause and at any time upon delivery of two months' notice. Purchases from this supplier were $64.5 million , $47.9 million and $41.7 million for the years ended December 31, 2017 , December 31, 2016 and December 31, 2015 , respectively. Property and equipment Property and equipment less accumulated depreciation are stated at historical cost. The Company's expenditures for property and equipment are primarily for computer equipment and software used in the administration of its business, and for leasehold improvements to its leased facilities. The Company also develops molds and dies used in long-term manufacturing arrangements with suppliers and for production automation equipment used in the manufacturing of consumable blister card components. Depreciation and amortization is computed by use of the straight-line method over the estimated useful lives of the assets as stated below: Computer equipment and related software 3 - 5 years Leasehold and building improvements Shorter of the lease term or the estimated useful life Furniture and fixtures 5 - 7 years Equipment 3 - 12 years Depreciation and amortization of property and equipment was $16.2 million , $15.0 million and $12.8 million for the years ended December 31, 2017 , December 31, 2016 and December 31, 2015 , respectively. The Company capitalizes costs related to computer software developed or obtained for internal use in accordance with ASC 350-40, Internal-Use Software . Software obtained for internal use has generally been enterprise-level business and finance software that the Company customizes to meet its specific operational needs. Costs incurred in the application development phase are capitalized and amortized over their useful lives, which is generally five years. Costs recognized in the preliminary project phase and the post-implementation phase are expensed as incurred. The Company capitalized $0.4 million and $2.2 million of costs related to the application development of enterprise-level software that was included in property and equipment during the years ended December 31, 2017 and December 31, 2016 , respectively. Software development costs The Company capitalizes software development costs in accordance with ASC 985-20, Costs of Software to Be Sold, Leased, or Marketed , under which certain software development costs incurred subsequent to the establishment of technological feasibility may be capitalized and amortized over the estimated lives of the related products. The Company establishes feasibility when it completes a working model and amortizes development costs over the estimated lives of the related products ranging from three to five years. The Company capitalized software development costs of $15.0 million and $14.3 million which are included in other assets as of December 31, 2017 and December 31, 2016 , respectively. The Company recorded $9.7 million , $7.1 million and $5.8 million to cost of revenues for amortization of capitalized software development costs for the years ended December 31, 2017 , December 31, 2016 and December 31, 2015 , respectively. All development costs prior to the completion of a working model are recognized as research and development expense. Deferred revenue Deferred revenue arise when customers have been billed and/or have received products and/or services in advance of revenue recognition. The Company's deferred revenue, net, presented as short term consists of (i) unearned revenue on sale of equipment for which installation has not been completed, net of deferred cost of sales for such equipment, and (ii) the current portion of unearned service contracts for which revenue is recognized over their duration. Long-term deferred revenue includes long term portion of unearned service contracts. Business combinations The Company uses the acquisition method of accounting under the authoritative guidance on business combinations. Each acquired company’s operating results are included in the Company's Consolidated Financial Statements starting on the date of acquisition. The purchase price is equivalent to the fair value of consideration transferred. Tangible and identifiable intangible assets acquired and liabilities assumed as of the date of acquisition are recorded at the acquisition date fair value. Goodwill is recognized for the excess of purchase price over the net fair value of assets acquired and liabilities assumed. Amounts allocated to assets and liabilities are based upon fair values. Such valuations require management to make significant estimates and assumptions, especially with respect to the identifiable intangible assets. Management makes estimates of fair value based upon assumptions believed to be reasonable and that of a market participant. These estimates are based on historical experience and information obtained from the management of the acquired companies and the estimates are inherently uncertain. The separately identifiable intangible assets generally include customer relationships, technology, and trade names. Goodwill and acquired intangible assets Goodwill. The Company reviews goodwill for impairment on an annual basis on the first day of the fourth quarter of each year at the reporting unit level. The Company's reporting units are the same as its operating segments, which are Automation and Analytics and Medication Adherence. A qualitative assessment is initially made to determine whether it is necessary to perform quantitative testing. A qualitative assessment includes, among others, consideration of: (i) past, current and projected future earnings and equity; (ii) recent trends and market conditions; and (iii) valuation metrics involving similar companies that are publicly-traded and acquisitions of similar companies, if available. If this qualitative assessment indicates that it is more likely than not that impairment exists, or if the Company decides to bypass this option, it proceeds to the quantitative assessment. The quantitative assessment involves a comparison between the estimated fair values of the Company's reporting units with their respective carrying amounts including goodwill. If the carrying value exceeds estimated fair value, the Company will record an impairment charge based on that difference. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. To determine each reporting unit's fair value under the quantitative approach, the Company uses a combination of income and market approaches, equally weighting the two approaches, such as estimated discounted future cash flows of that reporting unit, multiples of earnings or revenues, and analysis of recent sales or offerings of comparable entities. The Company also considers its market capitalization on the date of the analysis to ensure the reasonableness of the sum of its reporting units’ fair value. The Company performed a quantitative impairment analysis as of October 1, 2017 for its Medication Adherence reporting unit. The Company determined that the fair value of this reporting unit exceeded the carrying value by more than 40%, and thus no impairment was indicated. Additionally, the Company performed a qualitative impairment assessment analysis as of October 1, 2017 for its Automation and Analytics reporting unit taking into consideration past, current and projected future earnings, recent trends and market conditions; and valuation metrics involving similar companies that are publicly-traded. Based on the result of this analysis an impairment does not exist as of December 31, 2017. Intangible assets. In connection with the Company's acquisitions, it generally recognizes assets for customer relationships, backlog, developed technology, and trade names. Intangible assets are carried at cost less accumulated amortization. Such amortization is provided on a straight-line basis or on an accelerated basis based on a pattern of economic benefit that is expected to be obtained over the estimated useful lives of the respective assets, generally from one to 30 years. Amortization for developed technology and backlog is recognized in cost of revenues, and amortization for customer relationships, non-compete agreements, and trade names is recognized in selling, general and administrative expenses. The Company assesses the impairment of identifiable intangible assets whenever events or changes in circumstances indicate that an asset's carrying amount may not be recoverable. Recoverability of an asset is measured by the comparison of the carrying amount to the sum of the undiscounted estimated future cash flows the asset is expected to generate, offset by estimated future costs to dispose of the product to which the asset relates. If an asset is considered to be impaired, the amount of such impairment would be measured as the difference between the carrying amount of the asset and its fair value. The Company's cash flow assumptions are based on historical and forecasted future revenue, operating costs, and other relevant factors. Assumptions and estimates about the remaining useful lives of the Company's intangible assets are subjective and are affected by changes to its business strategies. If management’s estimates of future operating results change, or if there are changes to other assumptions, the estimate of the fair value of the Company's assets could change significantly. Such change could result in impairment charges in future periods, which could have a significant impact on the Company's operating results and financial condition. For the years ended December 31, 2017 and December 31, 2016, there were no events or changes in circumstances to indicate that intangible assets carrying amounts may not be recoverable. Valuation of share-based awards The Company accounts for share-based compensation in accordance with ASC 718, Stock Compensation ("ASC 718"). The Company recognizes compensation expense related to stock-based compensation based on the grant date estimated fair value. The fair value of stock options ("options") on the grant date is estimated using the Black-Scholes option pricing model, which requires the following inputs: expected life, expected volatility, risk-free interest rate, expected dividend yield rate, exercise price, and closing price of its common stock on the date of grant. The expected volatility is based on a combination of historical and market-based implied volatility, and the expected life of the awards is based on the Company's historical experience of employee stock option exercises, including forfeitures. Expense is recognized on a straight-line basis over the requisite service period. The fair value of Restricted Stock Units ("RSUs") is based on the stock price on the grant date. The fair value of Restricted Stock Awards (“RSAs”) is their intrinsic value, which is the difference between the fair value of the underlying stock at the measurement date and the purchase price. The RSUs and RSAs are subject to a service vesting condition and are recognized on a straight-line basis over the requisite service period. The fair value of PSUs with service and market conditions is estimated using a Monte Carlo simulation model applying multiple awards approach. Expense is recognized when it is probable that the performance condition will be met using the accelerated attribution method over the requisite service period. The valuation assumptions used in estimating the fair value of employee share-based awards may change in future periods. Accounting for income taxes The Company records an income tax provision for (benefit from) the anticipated tax consequences of the reported results of operations. In accordance with U.S. GAAP, the provision for (benefit from) income taxe

Business Combinations

Business Combinations	12 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Business Combinations	Business Combinations 2017 Acquisitions On April 12, 2017, the Company completed the acquisition of all of the membership interest of Dixie Drawl, LLC d/b/a InPharmics ("InPharmics"). InPharmics is a technology and services company that provides advanced pharmacy informatics solutions to hospital pharmacies. The total consideration for the transaction was $5.0 million , net of cash acquired of $0.3 million . Approximately $0.5 million of the total consideration was classified as a long-term liability for potential settlement of performance obligations. The Company accounted for the acquisition of InPharmics in accordance with the authoritative guidance on business combinations; therefore, the tangible and intangible assets acquired and liabilities assumed were recorded at fair value on the acquisition date. The purchase price was preliminary allocated to intangible assets in the amount of $1.9 million , which included developed technology and customer contracts, with the remainder allocated to goodwill. The results of the InPharmics' operations have been included in our consolidated results of operations, and presented as part of the Automation and Analytics segment. 2016 Acquisition Activity On January 5, 2016, the Company completed the acquisition of all of the membership interests of Aesynt. Aesynt is a provider of automated medication management systems, including dispensing robots with storage solutions, medication storage and dispensing carts and cabinets, I.V. sterile preparation robotics and software, including software related to medication management. The total consideration was $271.5 million , net of cash acquired of $8.2 million . The results of Aesynt's operations have been included in our consolidated results of operations as of the time of the acquisition, and presented as part of the Automation and Analytics segment. On December 8, 2016, the Company completed its acquisition of ateb, Inc., and Ateb Canada Ltd. (together, “Ateb”) for $40.7 million of cash consideration, net of $0.9 million cash on hand. The cash consideration, included the repayment of Ateb indebtedness and other adjustments provided for in the Ateb's Securities Purchase Agreement. Ateb is a provider of pharmacy-based patient care and medication synchronization solutions to independent and chain pharmacies. The results of Ateb's operations have been included in our consolidated results of operations as of the time of the acquisition, and presented as part of the Medication Adherence segment. The Company accounted for the acquisitions of Aesynt and Ateb in accordance with the authoritative guidance on business combinations; therefore, the tangible and intangible assets acquired and liabilities assumed were recorded at fair value on the acquisition dates, respectively. The following table represents the allocation of the purchase price to the assets acquired and the liabilities assumed by the Company during each acquisition, respectively, reconciled to the purchase price transferred included in the Company's Consolidated Balance Sheet: Aesynt Ateb Total (In thousands) Cash $ 8,164 $ 902 $ 9,066 Accounts receivable 43,312 7,761 51,073 Inventory 19,021 225 19,246 Other current assets 3,787 1,239 5,026 Total current assets 74,284 10,127 84,411 Property and equipment 10,389 2,447 12,836 Intangible assets 123,700 12,500 136,200 Goodwill 163,599 24,232 187,831 Other non-current assets 968 334 1,302 Total assets 372,940 49,640 422,580 Current liabilities 26,753 4,895 31,648 Deferred revenue, net 25,512 2,776 28,288 Non-current deferred tax liabilities 38,622 — 38,622 Other non-current liabilities 2,431 367 2,798 Total liabilities 93,318 8,038 101,356 Total purchase price 279,622 41,602 321,224 Total purchase price, net of cash received $ 271,458 $ 40,700 $ 312,158 The $163.6 million of goodwill arising from the Aesynt acquisition is primarily attributed to sales of future products and services and Aesynt's assembled workforce. The goodwill has been assigned to the Automation and Analytics segment and is not deductible for tax purposes. Since the acquisition, the Company adjusted the preliminary value assigned to goodwill by $1.2 million to reflect measurement period adjustments related to accounts receivable, inventory, and other assets and liabilities (inclusive of deferred taxes) of $1.6 million , $1.1 million and ($3.9) million , respectively. The $24.2 million of goodwill arising from the Ateb acquisition is primarily attributed to sales of future products and services and Ateb's assembled workforce. Since the acquisition, the Company adjusted the preliminary value assigned to goodwill by $3.4 million to reflect adjustments related to accounts receivable, other non-current assets and other accrued liabilities of $0.1 million , $0.7 million and $2.6 million , respectively. Intangible assets eligible for recognition separate from goodwill were those that satisfied either the contractual/legal criterion or the separability criterion in the accounting guidance. The identifiable intangible assets acquired and their estimated useful lives for amortization are as follows: Aesynt Ateb Fair value Weighted Fair value Weighted (In thousands) (In years) (In thousands) (In years) Customer relationships $ 58,200 14-16 $ 8,900 12 Developed technology 38,800 8 3,400 5 Backlog 20,200 1-3 — - In-process research and development ("IPR&D") (1) 3,900 - — - Non-compete 1,800 3 100 1 Trade names 800 1 100 1 Total purchased intangible assets $ 123,700 $ 12,500 (1) The amortization of the in-process R&D assets begins when the in-process R&D projects are complete. Aesynt Acquisition Customer relationships represent the fair value of the underlying relationships and agreements with Aesynt’s customers, acquired developed technology represents the fair value of Aesynt products that have reached technological feasibility and were part of Aesynt’s product offerings at the date of acquisition, backlog represents the fair value of sales order product backlog at the date of acquisition, non-compete intangible asset represents the fair value of non-compete agreements with former key members of Aesynt's management, and trade name represents the fair value of brand and name recognition associated with the marketing of Aesynt’s products and services. In-process research and development ("IPR&D") represents the fair value of incomplete Aesynt research and development projects that had not reached technological feasibility as of the date of acquisition. Incremental costs incurred for those projects are expensed as incurred in research and development. The fair value of Aesynt trade names, acquired developed technology, and acquired IPR&D was determined based on an income approach using the relief-from-royalty method at the royalty rates of 0.5% , 4% to 8% and 12.5% , respectively. The fair value of customer relationships, backlog, and non-compete intangible assets were determined based on an income approach using the discounted cash flow method, at the discounted rates of 13% , 10% and 13% , respectively. The intangible assets, except customer relationship and IPR&D, are being amortized over their estimated useful lives using the straight line method of amortization. The customer relationship intangible asset is being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained. In accordance with authoritative guidance, the IPR&D is accounted for as an indefinite-lived intangible asset until completion or abandonment of the associated research and development efforts. IPR&D is tested for impairment during the period it is considered an indefinite lived asset. IPR&D related projects are expected to be completed in two to three years. As of December 31, 2017 , none of the IPR&D projects have been completed, and they have progressed as previously estimated. Ateb Acquisition Customer relationships represent the fair value of the underlying relationships and agreements with Ateb’s customers expected to result in future sales, acquired developed technology represents the fair value of Ateb intellectual property incorporated in their products, non-compete intangible asset represents the fair value of non-compete agreements with former key members of Ateb's management, and trade name represents the fair value of brand and name recognition associated with the marketing of Ateb’s products and services. The fair value of Ateb trade names and acquired developed technology was determined based on an income approach using the relief-from-royalty method at the royalty rates of 0.5% and 5% to 6% , respectively. The fair value of customer relationships, and non-compete intangible assets were determined based on an income approach using the discounted cash flow method, both using a 15% discount rate. The intangible assets for non-compete agreements and trade name are being amortized over their estimated useful lives using the straight line method of amortization. The intangible assets for customer relationship and developed technology are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained. The Company incurred approximately $9.3 million in acquisition-related costs related to the Aesynt acquisition of which $6.4 million and $2.9 million were recognized in the years ended December 31, 2016 and 2015 , respectively. These costs are included in selling, general and administrative expenses in the Company's Consolidated Statement of Operations. During the year ended December 31, 2016 , the Company incurred and expensed approximately $1.7 million of acquisition-related costs for Ateb. Pro forma financial information The following table presents certain unaudited pro forma information for illustrative purposes only, for the years ended December 31, 2017 , December 31, 2016 and December 31, 2015 as if these acquisitions had been acquired on January 1, 2015. The pro forma information is not indicative of what would have occurred had the acquisitions taken place on January 1, 2015. The unaudited pro forma information combines the historical results of the acquisitions with the Company's consolidated historical results and includes certain adjustments reflecting the estimated impact of fair value adjustments for the respective periods. The pro forma adjustments include the impact of fair value adjustment related to deferred revenue, inventory fair value adjustment, amortization of intangible assets, stock-based compensation expense, interest expense and amortization of deferred issuance cost, and certain classification to conform to the Company's accounting policies. Twelve months ended December 31, 2017 2016 2015 (in thousands, except per share data) Pro forma net revenues $ 716,723 $ 719,799 $ 523,241 Pro forma net income (loss) $ 20,770 $ (1,044 ) $ 2,245 Pro forma net income (loss) per share $ 0.54 $ (0.03 ) $ 0.06 Weighted average number of shares 38,712 36,156 36,699

Net Income Per Share

Net Income Per Share	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Net Income Per Share	Net Income Per Share Basic net income per share is computed by dividing net income for the period by the weighted-average number of shares outstanding during the period. Diluted net income per share is computed by dividing net income for the period by the weighted-average number of shares, less shares repurchased, plus, if dilutive, potential common stock outstanding during the period. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards and restricted stock units computed using the treasury stock method. The anti-dilutive weighted-average dilutive shares related to stock award plans are excluded from the computation of the diluted net income per share. The calculation of basic and diluted net income per share is as follows: Year Ended December 31, 2017 2016 2015 (In thousands, except per share data) Net income $ 20,605 $ 603 $ 30,760 Weighted-average shares outstanding — basic 37,483 36,156 35,857 Add: Dilutive effect of employee stock plans 1,229 708 861 Weighted-average shares outstanding — diluted 38,712 36,864 36,718 Net income per share — basic $ 0.55 $ 0.02 $ 0.86 Net income per share — diluted $ 0.53 $ 0.02 $ 0.84 Anti-dilutive weighted-average shares related to stock award plans 501 1,345 555

Cash and Cash Equivalents and F

Cash and Cash Equivalents and Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Cash and Cash Equivalents and Fair Value of Financial Instruments	Cash and Cash Equivalents and Fair Value of Financial Instruments Cash and cash equivalents of $32.4 million and $54.5 million as of December 31, 2017 and December 31, 2016 , respectively, consisted of demand deposits only. Fair value hierarchy The Company measures its financial instruments at fair value. The Company’s cash equivalents are classified within Level 1 of the fair value hierarchy as they are valued primarily using quoted market prices utilizing market observable inputs. The Company's interest rate swap contracts and foreign currency contracts are classified within Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments. The Company's contingent consideration liability related to the Avantec acquisition and was classified as Level 3 as valuation inputs were unobservable in the market and significant to the instrument’s valuation. The Company determined the final payout amount for the remaining contingent consideration and reduced the liability from $3.0 million to $2.4 million . The reduction of the contingent liability resulted in a gain of $0.6 million which is recorded in the "Interest and other income (expense), net" line in the Consolidated Statement of Operations for the year ended December 31, 2016. During the year ended December 31, 2017, the Company concluded that the final payout had been earned and paid out $2.4 million during the third quarter of 2017. The following table represents the fair value hierarchy of the Company’s financial assets measured at fair value as of December 31, 2017 : Level 1 Level 2 Level 3 Total (In thousands) Interest rate swap contracts $ — $ 1,378 $ — $ 1,378 Total financial assets $ — $ 1,378 $ — $ 1,378 The following table represents the fair value hierarchy of the Company’s financial assets measured at fair value as of December 31, 2016 : Level 1 Level 2 Level 3 Total (In thousands) Interest rate swap contracts $ — $ 1,245 $ — $ 1,245 Total financial assets $ — $ 1,245 $ — $ 1,245 Contingent consideration liability — — 2,400 2,400 Total financial liabilities $ — $ — $ 2,400 $ 2,400 There have been no transfers between fair value measurement levels during the years ended December 31, 2017 and December 31, 2016 . Foreign Currency Risk Management The Company operates in foreign countries, which expose it to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, the most significant of which is the British Pound and the Euro. In order to manage foreign currency risk, at times the Company enters into foreign exchange forward contracts to mitigate risks associated with changes in spot exchange rates of mainly non-functional currency denominated assets or liabilities of the Company's foreign subsidiaries. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. By working only with major banks and closely monitoring current market conditions, the Company seeks to limit the risk that counterparties to these contracts may be unable to perform. The foreign exchange forward contracts are measured at fair value and reported as other current assets or accrued liabilities on the Consolidated Balance Sheets. The derivative instruments the Company uses to hedge this exposure are not designated as hedges. Any gains or losses on the foreign exchange forward contracts are recognized in earnings as Other Income/Expense in the period incurred in the Consolidated Statements of Operations. The Company does not enter into derivative contracts for trading purposes. At December 31, 2017 and December 31, 2016 , the Company had no outstanding foreign exchange forward contracts. Interest Rate Swap Contracts The Company uses interest rate swap agreements to protect the Company against adverse fluctuations in interest rates by reducing its exposure to variability in cash flows relating to interest payments on a portion of its outstanding debt. The Company's interest rate swaps, which are designated as cash flow hedges, involve the receipt of variable amounts from counterparties in exchange for the Company making fixed-rate payments over the life of the agreements. The Company does not hold or issue any derivative financial instruments for speculative trading purposes. During 2016, the Company entered into an interest rate swap agreement with a combined notional amount of $100.0 million with one counter-party that is effective beginning on June 30, 2016 and maturing on April 30, 2019. The swap agreement requires the Company to pay a fixed rate of 0.8% and provides that the Company will receive a variable rate based on the one month LIBOR rate subject to LIBOR floor of 0.0% . Amounts payable by or due to the Company will be net settled with the respective counter-party on the last business day of each month, commencing July 31, 2016. The fair value of the interest rate swap agreements at December 31, 2017 and December 31, 2016 was $1.4 million and $1.2 million , respectively. There were no amounts reclassified into current earnings due to ineffectiveness during the periods presented.

Balance Sheet Components

Balance Sheet Components	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Components	Balance Sheet Components Balance sheet details as of December 31, 2017 and December 31, 2016 are presented in the tables below: December 31, 2017 2016 (In thousands) Inventories: Raw materials $ 22,750 $ 14,322 Work in process 9,818 7,800 Finished goods 63,569 47,175 Total inventories $ 96,137 $ 69,297 Prepaid expenses Prepaid commissions $ 15,671 $ 13,176 Other prepaid expenses 20,389 15,470 Total prepaid expense $ 36,060 $ 28,646 Property and equipment: Equipment $ 69,550 $ 64,384 Furniture and fixtures 6,534 6,517 Leasehold improvements 10,976 9,778 Software 37,168 35,607 Construction in progress 9,813 7,211 Property and equipment, gross 134,041 123,497 Accumulated depreciation and amortization (91,446 ) (81,486 ) Total property and equipment, net $ 42,595 $ 42,011 Other long term assets: Capitalized software, net $ 38,599 $ 33,233 Other assets 1,242 1,818 Total other long term assets, net $ 39,841 $ 35,051 Accrued liabilities: Advance payments from customers $ 7,779 $ 7,030 Rebates and lease buyouts 5,428 4,025 Group purchasing organization fees 3,449 3,737 Taxes payable 9,183 4,003 Other accrued liabilities 9,854 12,400 Total accrued liabilities $ 35,693 $ 31,195 The following table summarizes the changes in accumulated balances of other comprehensive income (loss) for the years ended December 31, 2017 and December 31, 2016 : Foreign currency translation adjustments Unrealized gain (loss) on interest rate swap hedges Total (In thousands) Balance as of December 31, 2015 $ (2,730 ) $ — $ (2,730 ) Other comprehensive income (loss) before reclassifications (8,034 ) 1,385 (6,649 ) Amounts reclassified from other comprehensive income (loss) — (140 ) (140 ) Net current-period other comprehensive income (loss), net of tax (8,034 ) 1,245 (6,789 ) Balance as of December 31, 2016 (10,764 ) 1,245 (9,519 ) Other comprehensive income (loss) before reclassifications 3,810 409 4,219 Amounts reclassified from other comprehensive income (loss), net of tax — (813 ) (813 ) Net current-period other comprehensive income (loss), net of tax 3,810 (404 ) 3,406 Balance as of December 31, 2017 $ (6,954 ) $ 841 $ (6,113 )

Net Investment in Sales-Type Le

Net Investment in Sales-Type Leases	12 Months Ended
	Dec. 31, 2017
Leases [Abstract]
Net Investment in Sales-Type Leases	Net Investment in Sales-Type Leases On a recurring basis, the Company enters into sales-type lease transactions which vary in length from one to five years . The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at December 31, 2017 and December 31, 2016 : December 31, 2017 2016 (In thousands) Net minimum lease payments to be received $ 25,899 $ 33,591 Less: unearned interest income portion (1,695 ) (2,763 ) Net investment in sales-type leases 24,204 30,828 Less: short-term portion (1) (8,769 ) (10,243 ) Long-term net investment in sales-type leases $ 15,435 $ 20,585 (1) The short-term portion of the net investments in sales-type leases is included in the other current assets on the Consolidated Balance Sheets. The Company evaluates its sales-type leases individually and collectively for impairment. The allowance for credit losses were $0.2 million and $0.3 million as of December 31, 2017 and December 31, 2016 , respectively. At December 31, 2017 , the future minimum lease payments to be received under sales-type leases are as follows: Year ended December 31, (In thousands) 2018 $ 8,769 2019 6,708 2020 4,772 2021 2,992 2022 2,265 Thereafter 393 Total $ 25,899

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill The changes in the carrying amount of goodwill are as follows: Automation and Analytics Medication Adherence Total (In thousands) Net balance as of December 31, 2015 $ 54,316 $ 93,590 $ 147,906 Additions (1) 163,599 20,832 184,431 Adjustments (2) (2,833 ) (1,780 ) (4,613 ) Net balance as of December 31, 2016 215,082 112,642 327,724 Additions (3) 3,113 3,400 6,513 Adjustments (2) 2,656 858 3,514 Net balance as of December 31, 2017 $ 220,851 $ 116,900 $ 337,751 _________________________________________________ (1) Additions to goodwill as a result of the Aesynt acquisition in January 2016 and Ateb acquisition in December 2016. (2) Adjustments reflect foreign currency exchange rate fluctuations. (3) Additions to goodwill in Automation and Analytics segment was a result of the InPharmics acquisition in April 2017. Additions to goodwill in Medication Adherence segment represent adjustments to the preliminary value assigned to goodwill in connection with Ateb acquisition to reflect measurement period adjustments related to accounts receivable, other non-current assets and other liabilities of $0.1 million , $0.7 million and $2.6 million , respectively. Intangible assets, net The carrying amounts of intangible assets and useful lives as of December 31, 2017 were as follows: December 31, 2017 Gross carrying amount Accumulated amortization Foreign currency exchange rate fluctuations Net carrying amount Useful life (years) (In thousands, except for years) Customer relationships $ 133,913 $ (33,526 ) $ 65 $ 100,452 1 - 30 Acquired technology 74,593 (21,523 ) 34 53,104 3 - 20 Backlog 21,712 (17,544 ) — 4,168 1 - 4 Trade names 8,716 (4,719 ) 6 4,003 1 - 12 Patents 3,296 (1,418 ) 2 1,880 2 - 20 Non-compete agreements 1,900 (1,300 ) — 600 3 In process technology 3,900 — — 3,900 - Total intangibles assets, net $ 248,030 $ (80,030 ) $ 107 $ 168,107 The carrying amounts of intangible assets and useful lives as of December 31, 2016 were as follows: December 31, 2016 Gross carrying amount Accumulated amortization Foreign currency exchange rate fluctuations Net carrying amount Useful life (years) (In thousands, except for years) Customer relationships $ 133,358 $ (20,930 ) $ (596 ) $ 111,832 1 - 30 Acquired technology 73,599 (13,287 ) (159 ) 60,153 3 - 20 Backlog 20,550 (14,083 ) — 6,467 1 - 3 Trade names 8,667 (3,887 ) (31 ) 4,749 1 - 12 Patents 3,154 (1,264 ) — 1,890 2 - 20 Non-compete agreements 1,900 (608 ) — 1,292 3 In-process technology 3,900 — — 3,900 - Total intangibles assets, net $ 245,128 $ (54,059 ) $ (786 ) $ 190,283 Amortization expense of intangible assets was $25.6 million , $36.1 million and $6.9 million for the years ended December 31, 2017 , December 31, 2016 and December 31, 2015 , respectively. The estimated future amortization expenses for intangible assets are as follows: For the year ended December 31, (In thousands) 2018 $ 23,433 2019 17,953 2020 16,739 2021 15,439 2022 13,973 Thereafter (excluding in-process technology) 76,670 Total $ 164,207

Debt and Credit Agreements

Debt and Credit Agreements	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Debt and Credit Agreement	Debt and Credit Agreements 2016 Senior Secured Credit Facility On January 5, 2016, the Company entered into a $400 million senior secured credit facility pursuant to a credit agreement, by and among the Company, the lenders from time to time party thereto, Wells Fargo Securities, LLC, as Sole Lead Arranger and Wells Fargo Bank, National Association, as administrative agent (the “Credit Agreement”). The Credit Agreement provides for (a) a five -year revolving credit facility of $200 million , which was subsequently increased pursuant to an amendment discussed below (the “Revolving Credit Facility”) and (b) a five -year $200 million term loan facility (the “Term Loan Facility” and together with the Revolving Credit Facility, the “Facilities”). In addition, the Credit Agreement includes a letter of credit sub-limit of up to $10 million and a swing line loan sub-limit of up to $10 million . The Credit Agreement expires on January 5, 2021, upon which date all remaining outstanding borrowings are due and payable. Loans under the Facilities bear interest, at the Company’s option, at a rate equal to either (a) the LIBOR Rate, plus an applicable margin ranging from 1.50% to 2.25% per annum based on the Company’s consolidated total net leverage ratio (as defined in the Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50% , and (iii) LIBOR for an interest period of one month, plus an applicable margin ranging from 0.50% to 1.25% per annum based on the Company’s consolidated total net leverage ratio (as defined in the 2016 Credit Agreement). Undrawn commitments under the Revolving Credit Facility will be subject to a commitment fee ranging from 0.20% to 0.35% per annum based on the Company’s consolidated total net leverage ratio on the average daily unused portion of the Revolving Credit Facility. A letter of credit participation fee ranging from 1.50% to 2.25% per annum based on the Company’s consolidated total net leverage ratio will accrue on the average daily amount of letter of credit exposure. The Company is permitted to make voluntary prepayments at any time without payment of a premium or penalty, except for any amounts relating to the LIBOR breakage indemnity as described in the Credit Agreement. The Company is required to make mandatory prepayments under the Term Loan Facility with (a) net cash proceeds from any issuances of debt (other than certain permitted debt) and (b) net cash proceeds from certain asset dispositions (other than certain asset dispositions) and insurance and condemnation events (subject to reinvestment rights and certain other exceptions). Loans under the Term Loan Facility will amortize in quarterly installments, equal to 5% per annum of the original principal amount thereof during the first two years, which shall increase to 10% per annum during the third and fourth years, and 15% per annum during the fifth year, with the remaining balance payable on January 5, 2021. The Company is required to make mandatory prepayments under the Revolving Credit Facility if at any time the aggregate outstanding principal amount of loans together with the total amount of outstanding letters of credit exceeds the aggregate commitments, with such mandatory prepayment to be equal to the amount of such excess. The Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends and other distributions. The Credit Agreement contains financial covenants that require the Company and its subsidiaries to not exceed a maximum consolidated total leverage ratio and maintain a minimum fixed charge coverage ratio. The Company’s obligations under the Credit Agreement and any swap obligations and banking services obligations owing to a lender (or an affiliate of a lender) are guaranteed by certain of its domestic subsidiaries and secured by substantially all of its and the subsidiary guarantors’ assets. In connection with entering into the Credit Agreement, and as a condition precedent to borrowing loans thereunder, the Company and certain of the Company’s other direct and indirect subsidiaries have entered into certain ancillary agreements, including, but not limited to, a collateral agreement and subsidiary guaranty agreement. The Company was in full compliance with all covenants as of December 31, 2017 . On January 5, 2016, the Company borrowed the full $200 million under the Term Loan Facility and $55 million under the Revolving Credit Facility to complete the Aesynt acquisition and pay related fees and expenses. On December 2, 2016, the Company borrowed an additional $40 million under the Revolver Credit Facility to complete the Ateb acquisition and pay related fees and expenses. During the year ended December 31, 2017, the Company borrowed $59.0 million under the Revolving Credit Facility to pay for the InPharmics acquisition and fund its operations. As of December 31, 2017 the Company has repaid $137.0 million borrowed under these Facilities which includes $102.5 million repaid during the year ended December 31, 2017 . On April 11, 2017, the parties entered into the First Amendment to Credit Agreement and Collateral Agreement (the "Amended Credit Agreement"). Under this amendment, (i) the maximum capital expenditures limit in any fiscal year for property, plant and equipment and software development increased from $35.0 million to $45.0 million , and (ii) the maximum limit for non-permitted investments increased from $10.0 million to $20.0 million . On December 26, 2017, the parties entered into another amendment (the "Amendment") to the Amended Credit Agreement. Pursuant to the Amendment, the Revolving Credit Facility provided for under the Amended Credit Agreement, was increased from $200.0 million to $315.0 million and certain other modifications to the Amended Credit Agreement were made, including amendments to certain negative covenants. In connection with these Facilities, the Company incurred $10.1 million of debt issuance costs which included an additional $2.1 million of incurred costs in connection with the Amendment signed in December 2017. The debt issuance costs were capitalized and presented as a direct deduction from the carrying amount of that debt liability. The debt issuance costs are being amortized to interest expense using the straight line method from issuance date through 2021. Interest expense (exclusive of fees and issuance cost amortization) was approximately $6.3 million , $5.3 million and zero for the years ended December 31, 2017 , December 31, 2016 and December 31, 2015 , respectively. The components of the Company’s debt obligations as of December 31, 2017 and December 31, 2016 are as follows: December 31, 2016 Additions/Borrowings Repayment / Amortization December 31, 2017 (In thousands) Term loan facility $ 192,500 $ — $ (10,000 ) $ 182,500 Revolving credit facility 68,000 59,000 (92,500 ) 34,500 Total debt under the facilities 260,500 59,000 (102,500 ) 217,000 Less: Deferred issuance cost (6,359 ) (2,106 ) 1,590 (6,875 ) Total Debt, net of deferred issuance cost $ 254,141 $ 56,894 $ (100,910 ) $ 210,125 Long term debt, current portion, net of deferred issuance cost 8,410 15,208 Long term debt, net of deferred issuance cost $ 245,731 $ 194,917 As of December 31, 2017 , the carrying amount of debt of $217.0 million approximates the comparable fair value of $220.9 million . The Company's debt facilities are classified as a Level 3 in the fair value hierarchy. The calculation of the fair value is based on a discounted cash flow model using observable market inputs and taking into consideration variables such as interest rate changes, comparable instruments, and long-term credit ratings. 2013 Credit Agreement In September 2013, the Company entered into a credit agreement (the "2013 Credit Agreement") with Wells Fargo Bank, National Association, as administrative agent, and the lenders from time to time party thereto. On January 5, 2016, this 2013 Credit Agreement was replaced by the credit facilities discussed above.

Deferred Revenue

Deferred Revenue	12 Months Ended
	Dec. 31, 2017
Deferred Revenue Disclosure [Abstract]
Deferred Revenue	Deferred Revenue Short-term deferred revenue of $86.1 million and $87.5 million includes deferred revenue from product sales and service contracts, net of deferred cost of sales of $16.9 million and $14.2 million as of December 31, 2017 and December 31, 2016 , respectively. The short-term deferred revenues from product sales relate to the delivered and invoiced products, pending installation and acceptance, expected to occur within the next twelve months. Long-term deferred revenue includes deferred revenue from the service contracts of $ 17.2 million and $ 17.1 million , as of December 31, 2017 and December 31, 2016 , respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Lease commitments The Company leases office space and office equipment under operating leases. Commitments under operating leases primarily relate to leasehold property and office equipment. Rent expense was $11.5 million , $9.8 million and $7.0 million for the years ended December 31, 2017 , December 31, 2016 and December 31, 2015 , respectively. The minimum future payments on non-cancelable operating leases are as follows: For the year ended December 31, (In thousands) 2018 $ 12,167 2019 11,945 2020 10,755 2021 10,471 2022 8,776 Thereafter 26,243 Total minimum future lease payments $ 80,357 Purchase obligations In the ordinary course of business, we issue purchase orders based on our current manufacturing needs. As of December 31, 2017 , the Company had non-cancelable purchase commitments of $ 58.1 million , which are expected to be paid within the next twelve months. Legal proceedings The Company is currently involved in various legal proceedings. As required under ASC 450, Contingencies , the Company accrues for contingencies when it believes that a loss is probable and that it can reasonably estimate the amount of any such loss. The Company has not recorded any accrual for contingent liabilities associated with the legal proceedings described below based on its belief that any potential loss, while reasonably possible, is not probable. Further, any possible range of loss in these matters cannot be reasonably estimated at this time. The Company believes that it has valid defenses with respect to legal proceedings pending against it. However, litigation is inherently unpredictable, and it is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of this contingency or because of the diversion of management's attention and the creation of significant expenses. On January 10, 2018, a lawsuit was filed against a number of individuals, governmental agencies and corporate entities, including the Company and one of its subsidiaries, Aesynt Incorporated (“Aesynt”), in the Circuit Court for the City of Richmond, Virginia, captioned Ruth Ann Warner, as Guardian of Jonathan James Brewster Warner v. Centra Health, Inc., et al. (Case No. CL18-152-1). The complaint seeks monetary recovery of compensatory and punitive damages in addition to certain declaratory relief based upon, as against the individuals, governmental agencies and corporate entities other than the Company and Aesynt, allegations of the use of excessive force, unlawful detention, false imprisonment, battery, simple and gross negligence and negligent hiring, detention and training and, as against the Company and Aesynt, claims of product liability, negligence and breach of implied warranties. The Company and Aesynt have not yet been served with the complaint. The Company intends to defend the lawsuit vigorously. Guarantees As permitted under Delaware law and the Company's certificate of incorporation and bylaws, the Company has agreed to indemnify its directors and officers against certain losses that they may suffer by reason of the fact that such persons are, were or become its directors or officers. The term of the indemnification period is for the director’s or officer’s lifetime and there is no limit on the potential amount of future payments that the Company could be required to make under these indemnification agreements. The Company has purchased a directors’ and officers’ liability insurance policy that may enable it to recover a portion of any future payments that it may be required to make under these indemnification agreements. Assuming the applicability of coverage and the willingness of the insurer to assume coverage and subject to certain retention, loss limits and other policy provisions, the Company believes it is unlikely that the Company will be required to pay any material amounts pursuant to these indemnification obligations. However, no assurances can be given that the insurers will not attempt to dispute the validity, applicability or amount of coverage without expensive and time-consuming litigation against the insurers. Additionally, the Company undertakes indemnification obligations in its ordinary course of business in connection with, among other things, the licensing of its products and the provision of its support services. In the ordinary course of the Company's business, the Company has in the past and may in the future agree to indemnify another party, generally its business affiliates or customers, against certain losses suffered or incurred by the indemnified party in connection with various types of claims, which may include, without limitation, claims of intellectual property infringement, certain tax liabilities, its gross negligence or intentional acts in the performance of support services and violations of laws. The term of these indemnification obligations is generally perpetual. In general, the Company attempts to limit the maximum potential amount of future payments that it may be required to make under these indemnification obligations to the amounts paid to it by a customer, but in some cases the obligation may not be so limited. In addition, the Company has in the past and may in the future warrant to its customers that its products will conform to functional specifications for a limited period of time following the date of installation (generally not exceeding 30 days) or that its software media is free from material defects. Sales contracts for certain of the Company's medication packaging systems often include limited warranties for up to six months, but the periodic activity and ending warranty balances the Company records have historically been immaterial. From time to time, the Company may also warrant that its professional services will be performed in a good and workmanlike manner or in a professional manner consistent with industry standards. The Company generally seeks to disclaim most warranties, including any implied or statutory warranties such as warranties of merchantability, fitness for a particular purpose, title, quality and non-infringement, as well as any liability with respect to incidental, consequential, special, exemplary, punitive or similar damages. In some states, such disclaimers may not be enforceable. If necessary, the Company would provide for the estimated cost of product and service warranties based on specific warranty claims and claim history. The Company has not been subject to any significant claims for such losses and has not incurred any material costs in defending or settling claims related to these indemnification obligations. Accordingly, the Company believes it is unlikely that the Company will be required to pay any material amounts pursuant to these indemnification obligations or potential warranty claims and, therefore, no material liabilities have been recorded for such indemnification obligations as of December 31, 2017 and December 31, 2016 .

Employee Benefits and Share-Bas

Employee Benefits and Share-Based Compensation	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Employee Benefits and Share-Based Compensation	Employee Benefits and Share-Based Compensation Stock purchase plan 1997 Employee Stock Purchase Plan The Company has an Employee Stock Purchase Plan ("ESPP"), under which employees can purchase shares of its common stock based on a percentage of their compensation, but not greater than 15% of their earnings; provided, however, an eligible employee's right to purchase shares of the Company's common stock may not accrue at a rate which exceeds $25,000 of the fair market value of such shares for each calendar year in which such rights are outstanding. The purchase price per share must be equal to the lower of 85% of the fair value of the common stock at the beginning of a 24 -month offering period or the end of each six -month purchasing period. There was a total of 2.4 million shares reserved for future issuance under the ESPP as of December 31, 2017 . Stock award plans 2009 Equity Incentive Plan The 2009 Equity Incentive Plan (“2009 Plan”), as amended, provides for the issuance of incentive stock options, restricted stock awards ("RSAs"), restricted stock unit awards ("RSUs"), performance stock unit awards ("PSUs"), and other stock awards to the Company's employees, directors and consultants. There were 5.5 million shares of common stock reserved for future issuance under the 2009 Plan as of December 31, 2017 . Options granted under the 2009 Plan become exercisable over periods of up to four years , with one-fourth of the shares vesting one year from the vesting commencement date with respect to initial grants, and the remaining shares vesting in 36 equal monthly installments thereafter. The exercise prices of the options is the fair market value of common stock on the date of grant. RSUs generally vest over periods of up to four years , with one-fourth of the shares vesting one year from the vesting commencement date with respect to initial grants, and the remaining shares vesting in 12 equal quarterly installments thereafter. Awards of restricted stock to non-employee directors are granted on the date of the annual meeting of stockholders and vest in full on the date of the next annual meeting of stockholders, provided such non-employee director remains a director on such date. The fair value of the awards on the date of issuance is amortized to expense from the date of grant to the date of vesting and are expensed ratably on a straight-line basis over the vesting period. PSUs granted to the Company’s executives might include performance and market conditions. PSUs become eligible for vesting when certain market or performance conditions are met. Share-based compensation expense The following table sets forth the total share-based compensation expense recognized in the Company's Consolidated Statements of Operations: Year Ended December 31, 2017 2016 2015 (In thousands) Cost of product and service revenues $ 3,478 $ 2,596 $ 2,111 Research and development 3,590 3,128 2,060 Selling, general and administrative 14,789 13,776 10,750 Total share-based compensation expense $ 21,857 $ 19,500 $ 14,921 The Company did not capitalize any share-based compensation as inventory as such amounts were not material for the years ended December 31, 2017 , December 31, 2016 and December 31, 2015 . Income tax benefits realized from share-based compensation were $8.2 million , $5.4 million and $5.0 million , for the years ended December 31, 2017 , December 31, 2016 and December 31, 2015 , respectively. Stock Options and ESPP Shares The following assumptions were used to value share options and ESPP shares granted pursuant to our equity incentive plans: Year Ended December 31, 2017 2016 2015 Stock Option Plans Risk-free interest rate 1.9 % 1.5 % 1.7 % Dividend yield — % — % — % Expected volatility 29.6 % 30.6 % 32.0 % Expected life (in years) 4.7 years 4.9 years 5.0 years Year Ended December 31, 2017 2016 2015 Employee Stock Purchase Plan Risk-free interest rate 0.52% - 1.39% 0.34% - 0.79% 0.03% - 0.79% Dividend yield — % — % — % Expected volatility 25.8% - 32.8% 25.8% - 34.8% 25.7% - 37.5% Expected life (in years) 0.5 - 2.0 0.5 - 2.0 0.5 - 2.0 Stock options activity A summary of the stock option activity under the 2009 Plan is presented below: Number of Shares Weighted-Average Exercise Price Weighted-Average Remaining Years Aggregate Intrinsic Value (In thousands, except per share data) Outstanding at December 31, 2016 3,214 $ 26.06 7.3 $ 26,331 Granted (Awarded) 1,045 $ 45.13 Exercised (Released) (813 ) $ 22.28 Expired (6 ) $ 27.54 Forfeited (117 ) $ 33.39 Outstanding at December 31, 2017 3,323 32.72 7.6 $ 53,953 Exercisable at December 31, 2017 1,350 23.87 5.8 33,293 Vested and expected to vest at December 31, 2017 and thereafter 3,323 32.72 7.6 $ 53,953 The weighted-average fair value per share of options granted during 2017 , 2016 and 2015 was $13.25 , $9.33 and $9.67 , respectively. The intrinsic value of options exercised during 2017 , 2016 and 2015 was $18.2 million , $5.6 million and $11.3 million , respectively. As of December 31, 2017 , total unrecognized compensation cost related to unvested stock options was $18.9 million , which is expected to be recognized over a weighted-average vesting period of 2.9 years . As of December 31, 2016 , total unrecognized compensation cost related to unvested stock options was $13.3 million , which is expected to be recognized over a weighted-average vesting period of 3.0 years . Employee Stock Purchase Plan activity For the year ended December 31, 2017 , employees purchased 0.5 million shares of common stock under the ESPP and an aggregate of 6.0 million shares were issued under the ESPP as of December 31, 2017 . The unrecognized compensation cost related to the shares to be purchased under the ESPP was approximately $0.9 million , and is expected to be recognized over a weighted-average period of 1.3 years as of December 31, 2017 . Restricted Stock Units and Restricted Stock Awards Summaries of the restricted stock activity under the 2009 Plan are presented below: Number of Shares Weighted-Average Grant Date Fair Value Weighted-Average Remaining Years Aggregate Intrinsic Value (In thousands, except per share data) Restricted Stock Units Non-vested at December 31, 2016 505 $ 31.42 1.6 $ 17,135 Granted (Awarded) 245 45.97 Vested (Released) (215 ) 30.41 Forfeited (34 ) 32.39 Non-vested at December 31, 2017 501 38.90 1.5 $ 24,293 The weighted-average grant date fair value per share of RSUs granted during 2017 , 2016 and 2015 was $45.97 , $32.58 and $31.44 , respectively. The total fair value of RSUs that vested in 2017 , 2016 and 2015 was $6.5 million , $4.8 million and $4.7 million , respectively. As of December 31, 2017 , total unrecognized compensation cost related to RSUs was $16.1 million , which is expected to be recognized over the remaining weighted-average vesting period of 2.7 years . As of December 31, 2016 , total unrecognized compensation cost related to RSUs was $12.8 million , which is expected to be recognized over the remaining weighted-average vesting period of 2.9 years. Number of Shares Weighted-Average Grant Date Fair Value (In thousands, except per share data) Restricted Stock Awards Non-vested at December 31, 2016 30 $ 31.57 Granted (Awarded) 23 41.10 Vested (Released) (30 ) 31.58 Non-vested at December 31, 2017 23 $ 41.07 The weighted-average grant date fair value per share of RSAs granted during 2017 , 2016 and 2015 was $41.10 , $31.59 and $36.05 , respectively. The total fair value of RSAs that vested in 2017 , 2016 and 2015 was $1.0 million , $1.2 million and $1.1 million , respectively. As of December 31, 2017 , total unrecognized compensation cost related to RSAs was $0.3 million , which is expected to be recognized over the remaining weighted-average vesting period of 0.4 years. As of December 31, 2016 , total unrecognized compensation cost related to RSAs was $0.4 million , which was expected to be recognized over the remaining weighted-average vesting period of 0.4 years . Performance-based Restricted Stock Units In 2011, the Company began incorporating performance-based restricted stock units ("PSUs") as an element of its executive compensation plans. In 2016, the Company granted 122,740 PSUs to its executive officers, all of which became eligible for vesting upon the achievement of a certain level of shareholder return. In 2017, the Company granted 147,830 PSUs to its executive officers, all, none or a portion of which may become eligible for vesting depending on the level of shareholder return for the period from March 1, 2017 through March 1, 2018. The fair value of a PSU award is determined using a Monte Carlo simulation model. The number of shares that vest at the end of the performance period depends on the percentile ranking of the total shareholder return for Omnicell stock over the performance period relative to the total shareholder return of each of the other companies in the NASDAQ Healthcare Index (the "Index"). For PSUs granted on February 8, 2017, stock price appreciation is calculated based on the trailing 20 -day average stock price just prior to the first trading day of March 2017, compared to the trailing 20 -day average stock price just prior to the first trading day of March 2018. For PSUs granted on February 4, 2016, stock price appreciation is calculated based on the trailing 20 -day average stock price just prior to the first trading day of March 2016, compared to the trailing 20 -day average stock price just prior to the first trading day of March 2017. On March 7, 2016, the Compensation Committee confirmed 66.0% as the percentile rank of the Company's 2016 total stockholder return. This resulted in 100% of the 2015 PSUs, or 60,000 shares, as eligible for further time-based vesting. The eligible PSUs will vest as follows: 25% of the eligible shares vested immediately on March 7, 2016 with the remaining eligible awards vesting in equal increments, semi-annually, over the subsequent three -year period beginning on June 15th and December 15th of the year after the date of grant and each subsequent year. Vesting is contingent upon continued service. Of the 60,000 shares eligible for time-based vesting under the 2015 PSUs, 45,000 shares have vested as of December 31, 2017 . On March 7, 2017, the Compensation Committee confirmed 71.5% as the percentile rank of the Company's 2017 total stockholder return. This resulted in 100% of the 2016 PSUs, or 122,740 shares, as eligible for further time-based vesting. The eligible PSUs will vest as follows: 25% of the shares vested immediately on March 7, 2017 with the remaining shares vesting on a semi-annual basis period of 36 months commencing on June 15, 2017. Vesting is contingent upon continued service. Of the 122,740 shares eligible for time-based vesting under the 2016 PSUs, 61,375 shares have vested as of December 31, 2017 . A summary of the performance-based restricted stock activity under the 2009 Plan is presented below: Number of Shares Weighted-Average Grant Date Fair Value Per Unit (In thousands, except per share data) Non-vested at December 31, 2016 184 $ 24.89 Granted (Awarded) 148 34.05 Vested (Released) (107 ) 24.36 Non-vested at December 31, 2017 225 $ 31.18 The weighted-average grant date fair value per share of PSUs granted during 2017 , 2016 and 2015 was $34.05 , $24.66 and $29.56 , respectively. The total fair value of PSUs that vested in 2017 , 2016 and 2015 was $2.6 million , $2.0 million and $1.9 million , respectively. As of December 31, 2017 , total unrecognized compensation cost related to PSUs was approximately $2.7 million , which is expected to be recognized over the remaining weighted-average period of 1.2 years. As of December 31, 2016 , total unrecognized compensation cost related to PSUs was approximately $1.6 million , which was expected to be recognized over the remaining weighted-average period of 1.2 years. Summary of Shares Reserved for Future Issuance under Equity Incentive Plans The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of December 31, 2017 : Number of Shares (In thousands) Share options outstanding 3,323 Non-vested restricted stock awards 749 Shares authorized for future issuance 1,398 ESPP shares available for future issuance 2,365 Total shares reserved for future issuance 7,835 401(k) Plan The Company has established a pre-tax savings plan under Section 401(k) of the Internal Revenue Code. The 401(k) Plan allows eligible employees in the United States to voluntarily contribute a portion of their pre-tax salary, subject to a maximum limit specified in the Internal Revenue Code. The Company matches 50% of employee contributions up to $2,500 , annually. The Company's contributions under this plan were $3.8 million , $1.9 million and $1.8 million in 2017 , 2016 and 2015 , respectively.

Stock Repurchases

Stock Repurchases	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Stock Repurchases	Stock Repurchases On August 2, 2016, the Board of Directors (the "Board") of the Company authorized a stock repurchase program providing for the repurchase of up to $50.0 million of the Company’s common stock (the “2016 Repurchase Program”). The 2016 Repurchase Program is in addition to the stock repurchase program approved by the Board on November 4, 2014 (the “2014 Repurchase Program”). As of December 31, 2017, the maximum dollar value of shares that may yet be purchased under the two repurchase programs was $54.9 million . The timing, price and volume of repurchases are to be based on market conditions, relevant securities laws and other factors. The stock repurchases may be made from time to time on the open market, in privately negotiated transactions or pursuant to a Rule 10b-18 plan, subject to the terms and conditions of that certain Amendment of the Amended Credit Agreement, dated as of December 26, 2017, among the Company, the Lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent. The stock repurchase program does not obligate the Company to repurchase any specific number of shares, and the Company may terminate or suspend the repurchase program at any time. During the years ended December 31, 2017 and 2016 , respectively, the Company made no repurchases of its outstanding common stock. During the year ended December 31, 2015, the Company repurchased approximately $50.0 million of shares.

Equity Offerings

Equity Offerings	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Equity Offerings	Equity Offerings On November 3, 2017, the Company entered into a Distribution Agreement (the “Distribution Agreement”) with J.P. Morgan Securities LLC, Wells Fargo Securities, LLC and HSBC Securities (USA) Inc., as its sales agents, pursuant to which the Company may offer and sell from time to time through the sales agents up to $125 million maximum aggregate offering price of the Company’s common stock. Sales of the common stock pursuant to the Distribution Agreement may be made in negotiated transactions or transactions that are deemed to be “at the market” offerings as defined in Rule 415 under the Securities Act, including sales made directly on the Nasdaq Stock Market, or sales made to or through a market maker other than on an exchange. For the year ended December 31, 2017, the Company received gross proceeds of $14.7 million from sales of its common stock under the Distribution Agreement and incurred issuance costs of $0.8 million on sales of approximately 294,000 shares of its common stock at an average price of approximately $49.85 per share.

Segment and Geographical Inform

Segment and Geographical Information	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Segment and Geographical Information	Segment and Geographical Information Segment Information The Company's Chief Operating Decision Maker ("CODM") is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company's segments using information about its revenues, gross profit, and income from operations. Such evaluation excludes general corporate-level costs that are not specific to either of the reportable segments and are managed separately at the corporate level. Corporate-level costs include expenses related to executive management, finance and accounting, human resources, legal, training and development, and certain administrative expenses. The two operating segments, which are the same as the Company's two reportable segments, are as follows: Automation and Analytics The Automation and Analytics segment is organized around the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems, and related software. The Automation and Analytics products are designed to enable the Company's customers to enhance and improve the effectiveness of the medication-use process, the efficiency of the medical-surgical supply chain, overall patient care and clinical and financial outcomes of medical facilities. Through modular configuration and upgrades, the Company's systems can be tailored to specific customer needs. The financial results of InPharmics acquired in the second quarter of 2017 and Aesynt acquired in the first quarter of 2016 are included in the Automation and Analytics segment. Medication Adherence The Medication Adherence segment includes solutions to assist patients to remain adherent to their medication regimens. These solutions are comprised of a variety of tools and aids that may be directly used by a pharmacist or a healthcare provider in their direct care for a patient, or the patient themselves, and include software based systems and medication adherence packaging. Software solutions primarily operate on the Patient Management Access Portal (PMAP), a subscription based software system which provides an environment for patient engagement by clinicians. Services running on PMAP include Time My Meds medication synchronization, immunization management, and a number of tools used by clinicians to manage patient engagement workflows. Medication Adherence packaging is designed either for patient use in care environments where there is a caregiver present or for environments where the patient cares for him or herself and includes the manufacturing and selling of consumable medication blister cards, packaging equipment and ancillary products and services. The financial results of Ateb acquired in the fourth quarter of 2016 are included in the Medication Adherence segment. The following table summarizes the financial performance of the Company's reporting segments: Year Ended December 31, 2017 2016 2015 Automation and Analytics Medication Total Automation and Analytics Medication Adherence Total Automation and Analytics Medication Adherence Total (In thousands) Revenues $ 590,392 $ 125,773 $ 716,165 $ 593,626 $ 98,997 $ 692,623 $ 390,321 $ 94,238 $ 484,559 Cost of revenues 308,443 85,634 394,077 310,967 67,856 378,823 171,943 64,686 236,629 Gross profit 281,949 40,139 322,088 282,659 31,141 313,800 218,378 29,552 247,930 Operating expenses 193,700 41,735 235,435 198,511 24,843 223,354 114,084 24,258 138,342 Income from operations $ 88,249 $ (1,596 ) 86,653 $ 84,148 $ 6,298 90,446 $ 104,294 $ 5,294 109,588 Corporate costs 80,899 83,965 60,956 Income from operations $ 5,754 $ 6,481 $ 48,632 _________________________________________________ Significant customers The Company contracts with Group Purchasing Organizations (“GPOs”), each of which functions as a purchasing agent on behalf of member hospitals and other healthcare providers, as well as with government entities and agencies. Pursuant to the terms of GPO agreements, each member contracts directly with Omnicell and can purchase Company’s product at pre-negotiated contract terms and pricing. The account receivable balances are with individual members of the GPOs, and therefore no significant concentration of credit risk exists. During our fiscal year ended December 31, 2017, December 31, 2016 and December 31, 2015 sales to members of the ten largest GPOs accounted for approximately 51.2% , 51.2% and 65.2% of total consolidated revenue, respectively. There were no customers that accounted for more than 10% of the Company's total revenues or accounts receivable balance at and for the years ended December 31, 2017, December 31, 2016 and December 31, 2015. Geographical Information Revenues Year Ended December 31, 2017 2016 2015 (In thousands) United States $ 617,268 $ 591,566 $ 403,375 Rest of world (1) 98,897 101,057 81,184 Total revenues $ 716,165 $ 692,623 $ 484,559 ___________________________________________ (1) No individual country represented more than 10% of the respective totals. Property and equipment, net Property and equipment, net is attributed to the geographic location in which it is located. Year Ended December 31, 2017 2016 2015 (In thousands) United States $ 34,899 $ 36,497 $ 29,506 Rest of world (1) 7,696 5,514 2,803 Total property and equipment, net $ 42,595 $ 42,011 $ 32,309 _________________________________________________ (1) No individual country represented more than 10% of the respective totals.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The following is a geographical breakdown of income (loss) before the provision for (benefit from) income taxes: Year Ended December 31, 2017 2016 2015 (In thousands) Domestic $ 19,889 $ 1,471 $ 51,089 Foreign (20,768 ) (3,419 ) (4,845 ) Income (loss) before provision for (benefit from) income taxes $ (879 ) $ (1,948 ) $ 46,244 The provision for (benefit from) income taxes consists of the following: Year Ended December 31, 2017 2016 2015 (In thousands) Current: Federal $ 2,430 $ 6,724 $ 13,840 State 1,852 1,323 2,475 Foreign 745 46 203 Total current income taxes 5,027 8,093 16,518 Deferred: Federal (16,118 ) (3,378 ) 846 State (2,612 ) (1,802 ) (379 ) Foreign (7,781 ) (5,464 ) (1,501 ) Total deferred income taxes (26,511 ) (10,644 ) (1,034 ) Total provision for (benefit from) income taxes $ (21,484 ) $ (2,551 ) $ 15,484 The provision for (benefit from) income taxes differs from the amount computed by applying the statutory federal tax rate as follows: Year Ended December 31, 2017 2016 2015 (In thousands) U.S. federal tax provision at statutory rate $ (308 ) $ (682 ) $ 16,181 State taxes 19 (311 ) 1,365 Non-deductible expenses 1,373 1,212 551 Acquisition costs — 845 239 Share-based compensation expense 39 1,941 748 Research tax credits (3,233 ) (2,075 ) (1,324 ) Domestic production deduction (621 ) (890 ) (1,133 ) Gain on investment — — (1,205 ) Tax audit settlement — (2,499 ) — Foreign rate differential 938 (154 ) 123 Stock option tax benefit (5,926 ) — — One-time Impact of the Tax Act (13,391 ) — — Other (374 ) 62 (61 ) Total provision for (benefit from) income taxes $ (21,484 ) $ (2,551 ) $ 15,484 Significant components of the Company's deferred tax assets (liabilities) are as follows: December 31, December 31, (In thousands) Deferred tax assets (liabilities): Deferred revenue $ 6,345 $ 5,857 Stock compensation 4,460 6,451 Inventory related items 2,441 2,915 Tax credit carry forwards 9,349 4,871 Reserves and accruals 3,960 4,675 Loss carry forwards 8,643 8,077 Other, net 1,307 847 Total net deferred tax assets 36,505 33,693 Intangibles (36,780 ) (57,427 ) Depreciation and amortization (14,338 ) (20,071 ) Prepaid expenses (4,512 ) (3,746 ) Total deferred tax liabilities (55,630 ) (81,244 ) Net deferred tax liabilities $ (19,125 ) $ (47,551 ) Deferred income tax assets (liabilities) are provided for temporary differences that will result in future tax deductions or future taxable income, as well as the future benefit of tax credit carry forwards. The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing temporary differences, projected future taxable income, tax planning strategies, and results of recent operations. On the basis of this evaluation, as of December 31, 2017 , no valuation allowances have been recorded in any jurisdiction. On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”). The Tax Act significantly impacts the future ongoing U.S. corporate income tax by, among things, lowering the U.S. corporate income tax rates and implementing a territorial tax system. At December 31, 2017, the Company has not completed the accounting for the tax effects of enactment of the Tax Act; however, the Company made a reasonable estimate of the effects on the existing deferred tax balances and the one-time transition tax. The reduction of the U.S. corporate tax rate required the Company to revalue the U.S. deferred tax assets and liabilities to the newly enacted federal rate of 21%. This resulted in a one-time benefit of $13.4 million in the fourth quarter of 2017. As part of the transition to the new territorial tax system, the Tax Act imposes a one-time tax on a deemed repatriation of historical earnings of foreign subsidiaries. Based on the current evaluation of the Company’s operations, no repatriation tax charge is anticipated as the Company is in an earnings deficit position for foreign subsidiaries. The Company will continue to assess the provision for income taxes as future guidance is issued, but does not currently anticipate significant revisions will be necessary. Any such revisions will be treated in accordance with the measurement period guidance outlined in Staff Accounting Bulletin No. 118. As of December 31, 2017 , the Company has $6.6 million of federal net operating loss carryforwards expiring 2038 and $6.1 million of state net operating loss carryforwards expiring at various dates beginning 2023. For income tax purposes, the Company has federal and California research tax credits carryforwards of $2.4 million and $8.8 million , respectively. Federal research tax credit carry forwards from prior years will begin to expire in 2035. California credits are available indefinitely to reduce cash taxes otherwise payable. It is the Company's practice and intention to reinvest the earnings of its non-U.S. subsidiaries in those operations. As of December 31, 2017 , the Company has not made a provision for U.S. federal income, withholding, and state income taxes on the outside basis difference related to certain foreign subsidiaries because earnings are intended to be indefinitely reinvested in operations outside the U.S. At December 31, 2017, the Company has not completed the accounting for the tax effects resulting from the enactment of the Act; however, the Company made a reasonable estimate of the effects. The Company is continuing to evaluate its plans for reinvestment under the Act, including its plans for reinvestment or repatriation of unremitted foreign earnings. Any revisions will be treated in accordance with the measurement period guidance outlined in Staff Accounting Bulletin No. 118. The Company files income tax returns in the United States and various states and foreign jurisdictions. In the normal course of business, the Company is subject to examination by taxing authorities, including major jurisdictions such as the United States, Germany, Italy, Netherlands and the United Kingdom. With few exceptions, as of December 31, 2017, the Company was no longer subject to U.S., state, and foreign examination for years before 2014, 2013, and 2014, respectively. The aggregate change in the balance of gross unrecognized tax benefits, which excludes interest and penalties, for the three years ended December 31, 2017 is as follows: (In thousands) Year Ended December 31, 2014 $ 8,485 Increases related to tax positions taken during a prior period 37 Decreases related to tax positions taken during the prior period (895 ) Increases related to tax positions taken during the current period 1,807 Decreases related to settlements — Decreases related to expiration of statute of limitations (284 ) Year Ended December 31, 2015 9,150 Increases related to tax positions taken during a prior period 244 Decreases related to tax positions taken during the prior period (1,980 ) Increases related to tax positions taken during the current period 6,724 Decreases related to settlements (2,178 ) Decreases related to expiration of statute of limitations (344 ) Year Ended December 31, 2016 11,616 Increases related to tax positions taken during a prior period 503 Decreases related to tax positions taken during the prior period (1,782 ) Increases related to tax positions taken during the current period 805 Decreases related to settlements — Decreases related to expiration of statute of limitations (401 ) Year Ended December 31, 2017 $ 10,741 As of December 31, 2017 the total amount of gross unrecognized tax benefits, if realized, would decrease the Company's tax expense by approximately $10.7 million . The Company recognizes interest and/or penalties related to uncertain tax positions in operating expenses accruing $0.3 million , $0.5 million , and $0.1 million for fiscal years 2017, 2016, and 2015 respectively. Accrued interest and penalties are included within other long-term liabilities on the consolidated balance sheets. The combined amount of cumulative accrued interest and penalties was approximately $1.4 million , $1.1 million , and $0.6 million as of fiscal years 2017, 2016, and 2015 respectively. The Company does not believe there will be any significant changes in its unrecognized tax positions over the next twelve months.

Restructuring Expenses

Restructuring Expenses	12 Months Ended
	Dec. 31, 2017
Restructuring and Related Activities [Abstract]
Restructuring Expenses	Restructuring Expenses On February 15, 2017, the Company announced its plan to reduce its workforce by approximately 100 full-time employees and close the Company’s Nashville, Tennessee and Slovenia facilities, which was concluded in fiscal year 2017. The total cost for the plan was $4.2 million , which includes employee severance cost of approximately $3.7 million , and facility-related costs of approximately $0.6 million . At December 31, 2017 the unpaid balance under this plan is $0.4 million related to facilities-related expenses. In the second quarter of 2016, the Company integrated its sales and field organizations in North America to better serve its customers which resulted in a reduction in headcount of 36 employees. Accordingly, the Company incurred approximately $1.7 million of restructuring expenses in the year ended December 31, 2016 , based on agreements with terminated employees covering salary and benefit continuation. For the year ended December 31, 2016 , the Company made payments of $1.7 million and the restructuring program was concluded.

Schedule II Valuation and Quali

Schedule II Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2017
Valuation and Qualifying Accounts [Abstract]
Schedule II Valuation and Qualifying Accounts	SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS Additions Balance at (1) Charged to (2) Debited (credited) to Other Accounts (3) Amount Written Off (4) Acquisition and translation adjustments (5) Balance at (1) (In thousands) Year ended December 31, 2015 Accounts receivable $ 1,206 $ 453 $ 28 $ (447 ) $ — $ 1,240 Investment in sales-type leases 162 (99 ) 106 — — 169 Total allowances deducted from assets $ 1,368 $ 354 $ 134 $ (447 ) $ — $ 1,409 Year ended December 31, 2016 Accounts receivable $ 1,240 $ 727 $ 77 $ (369 ) $ 3,121 $ 4,796 Investment in sales-type leases 169 85 — — — 254 Total allowances deducted from assets $ 1,409 $ 812 $ 77 $ (369 ) $ 3,121 $ 5,050 Year ended December 31, 2017 Accounts receivable $ 4,796 $ 1,008 $ 3 $ (402 ) $ 333 $ 5,738 Investment in sales-type leases 254 (62 ) — — — 192 Total allowances deducted from assets $ 5,050 $ 946 $ 3 $ (402 ) $ 333 $ 5,930 __________________________________________________ (1) Allowance for doubtful accounts. (2) Represents amounts charged to bad debt expense, increasing the allowance. (3) Represents amounts debited to trade accounts receivable as recoveries, increasing the allowance. (4) Represents amounts written-off from the allowance and trade accounts receivable. (5) Represents primarily purchase price adjustments and minor foreign currency translation adjustments.

Organization and Summary of S25

Organization and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Principles of consolidation	Principles of consolidation The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. GAAP and include all adjustments necessary for the fair presentation of the Company's consolidated financial position, results of operations and cash flows for the periods presented. The Consolidated Financial Statements include the Company's accounts as well as those of its wholly owned subsidiaries after the elimination of intercompany balances and transactions.
Reclassifications	Certain prior year amounts in the Consolidated Statement of Cash Flows have been reclassified to conform to the 2017 presentation with the adoption of Accounting Standards Update ("ASU") 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting . Additionally, see "Recently adopted authoritative guidance" section below for the effects of adoption of ASU 2016-09.
Use of estimates	Use of estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company's Consolidated Financial Statements and accompanying Notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. The Company's critical accounting policies are those that affect its financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, allowance for doubtful accounts and notes receivable from investment in sales-type leases, inventory valuation, capitalized software development costs, valuation and impairment of goodwill, purchased intangibles and long-lived assets, fair value of assets acquired and liabilities assumed in business combination, share-based compensation and accounting for income taxes.
Segment reporting	Segment reporting The Company's Chief Operating Decision Maker ("CODM") is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company's segments using information about its revenues, gross profit, and income from operations. Such evaluation excludes general corporate-level costs that are not specific to either of the reportable segments and are managed separately at the corporate level. Corporate-level costs include expenses related to executive management, finance and accounting, human resources, legal, training and development, and certain administrative expenses. See Note 14, Segment and Geographical Information, for additional information on segment reporting. The operating results of the recently acquired InPharmics, Aesynt, Mach4 and Avantec businesses are included in the Company's Automation and Analytics reportable segment. The operating results of the recently acquired Ateb business is included in the Medication Adherence reportable segment.
Foreign currency translation and remeasurement	Foreign currency translation and remeasurement Most of the Company's foreign subsidiaries use the local currency of their respective countries as their functional currency. The Company translates the assets and liabilities of such non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Revenue and expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recorded as foreign currency translation adjustments and included in accumulated other comprehensive income (loss) in stockholders’ equity. The Company’s foreign subsidiaries that use the U.S. dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the end of each period, and non-monetary assets and liabilities at historical rates. Gains and losses from such foreign currency remeasurement are recorded in interest and other income (expense). Foreign Currency Risk Management The Company operates in foreign countries, which expose it to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, the most significant of which is the British Pound and the Euro. In order to manage foreign currency risk, at times the Company enters into foreign exchange forward contracts to mitigate risks associated with changes in spot exchange rates of mainly non-functional currency denominated assets or liabilities of the Company's foreign subsidiaries. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. By working only with major banks and closely monitoring current market conditions, the Company seeks to limit the risk that counterparties to these contracts may be unable to perform. The foreign exchange forward contracts are measured at fair value and reported as other current assets or accrued liabilities on the Consolidated Balance Sheets. The derivative instruments the Company uses to hedge this exposure are not designated as hedges. Any gains or losses on the foreign exchange forward contracts are recognized in earnings as Other Income/Expense in the period incurred in the Consolidated Statements of Operations. The Company does not enter into derivative contracts for trading purposes.
Revenue recognition	Revenue recognition The Company earns revenues from sales of its medication and medical and surgical supply automation systems along with consumables and related services, which are sold in the healthcare industry, its principal market. Revenues are reported net of discounts and rebates provided to its customers. The Company's customer arrangements typically include one or more of the following deliverables: Products. Software-enabled equipment that manages and regulates the storage and dispensing of pharmaceuticals, consumable blister cards and packaging equipment and other medical supplies. Software. Additional software applications that enable incremental functionality of its equipment. Installation. Installation of equipment as integrated systems at customers' sites. Post-installation technical support. Phone support, on-site service, parts and access to unspecified software upgrades and enhancements, if and when available. Professional services. Other customer services, such as training and consulting. The Company recognizes revenue when the earnings process is complete, based upon its evaluation of whether the following four criteria have been met: Persuasive evidence of an arrangement exists. The Company uses signed customer contracts and signed customer purchase orders as evidence of an arrangement for leases and sales. For service engagements, the Company uses a signed services agreement and a statement of work to evidence an arrangement. Delivery has occurred. Equipment and embedded software product delivery is deemed to occur upon successful installation and receipt of a signed and dated customer confirmation of installation letter, providing evidence that the Company has delivered what a customer ordered. In instances of a customer self-installation, product delivery is deemed to have occurred upon receipt of a signed and dated customer confirmation letter. If a sale does not require installation, the Company recognizes revenue on delivery of products to the customer, including transfer of title and risk of loss, assuming all other revenue criteria are met. For existing distributors, where installation of equipment training has been previously provided and the distributor is certified to install the Company's equipment at the end-user customer facility, the Company recognizes revenue from sales of products to the distributor upon shipment assuming all other revenue criteria are met, net of allowance for rights of return or refund. For new distributors, where the Company has not provided installation of equipment training, revenue on the sales of products to the distributor is deferred until the distributor has completed the Distributor Training Program and has been certified to install the Company's equipment at the end-user facility. For the sale of consumable blister cards, the Company recognizes revenue when title and risk of loss of the products shipped have transferred to the customer, which usually occurs upon shipment from the Company's facilities. Assuming all other revenue criteria are met, the Company recognizes revenue for support services ratably over the related support services contract period. The Company recognizes revenue on training and professional services as they are performed. Fee is fixed or determinable. The Company assesses whether a fee is fixed or determinable at the outset of the arrangement based on the payment terms associated with the transaction. The Company has established a history of collecting under the original contract without providing concessions on payments, products or services. Collection is probable. The Company assesses the probability of collecting from each customer at the outset of the arrangement based on a number of factors, including the customer's payment history and its current creditworthiness. If, in the Company's judgment, collection of a fee is not probable, the Company defers revenue recognition until the uncertainty is removed, which generally means revenue is recognized upon the Company's receipt of cash payment assuming all other revenue criteria are met. The Company's historical experience has been that collection from its customers is generally probable. In arrangements with multiple deliverables, assuming all other revenue criteria are met, the Company recognizes revenue for individual delivered items if they have value to the customer on a standalone basis. The Company allocates arrangement consideration at the inception of the arrangement to all deliverables using the relative selling price method. This method requires the Company to determine the selling price at which each deliverable could be sold if it were sold regularly on a standalone basis. When available, the Company uses vendor-specific objective evidence ("VSOE") of the selling price. VSOE represents the price charged for a deliverable when it is sold separately, or for a deliverable not yet being sold separately, the price established by management with the relevant authority. The Company considers VSOE to exist when approximately 80% or more of its standalone sales of an item are priced within a reasonably narrow pricing range (plus or minus 15% of the median rates). The Company has established VSOE of the selling price for its post-installation technical support services and professional services. When VSOE of selling price is not available, third-party evidence ("TPE") of selling price for similar products and services is acceptable; however, the Company's offerings and market strategy differ from those of its competitors, such that it cannot obtain sufficient comparable information about third parties' prices. If neither VSOE nor TPE are available, the Company uses its best estimates of selling prices ("BESP"). The Company determines BESP considering factors such as market conditions, sales channels, internal costs and product margin objectives and pricing practices. The Company regularly reviews and updates its VSOE and BESP information. The relative selling price method allocates total arrangement consideration proportionally to each deliverable on the basis of its estimated selling price. In addition, the amount recognized for any delivered items cannot exceed that which is not contingent upon delivery of any remaining items in the arrangement. The Company also uses the residual method to allocate revenue between the software products that enable incremental equipment functionality, and thus are not deemed to deliver its essential functionality, and the related post-installation technical support, as these products and services continue to be accounted for under software revenue recognition rules. Under the residual method, the amount allocated to the undelivered elements equals VSOE of fair value of these elements. Any remaining amounts are attributed to the delivered items and are recognized when those items are delivered. A portion of the Company's sales are made through multi-year lease agreements. Under sales-type leases, the Company recognizes revenue for its hardware and software products net of lease execution costs such as post-installation product maintenance and technical support, at the net present value of the lease payment stream once its installation obligations have been met. The Company optimizes cash flows by selling a majority of its non-U.S. government leases to third-party leasing finance companies on a non-recourse basis. The Company has no obligation to the leasing company once the lease has been sold. Some of the Company's sales-type leases, mostly those relating to U.S. government hospitals which comprise approximately 33% of the lease receivable balance, are retained in-house. Interest income in these leases is recognized in product revenue using the effective interest method. The Company will adopt the ASU 2014-09, Revenue from Contracts with Customers, effective January 1, 2018. Please refer to “Recently issued authoritative guidance” which is included in Note 1 of this report.
Cash equivalents	Cash and Cash Equivalents and Fair Value of Financial Instruments. The Company classifies investments as cash equivalents if their original or remaining contractual maturity is three months or less at the date of purchase. Cash equivalents are carried at amounts that approximate fair value due to the short period of time to maturity. The Company's cash balances are maintained in demand deposit accounts with financial institutions of high credit quality. The Company continuously monitors the credit worthiness of the financial institutions in which it invests. The Company has not experienced any credit losses from its cash investments.
Foreign currency forward contracts and Interest rate swap agreements	Foreign currency forward contracts. The Company enters into foreign currency forward contracts to protect its business from the risk that exchange rates may affect the eventual cash flows resulting from intercompany transactions between Omnicell and its foreign subsidiaries. These transactions primarily arise as a result of products manufactured in the United States ("U.S") and sold to foreign subsidiaries in U.S. dollars rather than the subsidiaries' functional currencies. These forward contracts are considered to be financial derivative instruments and are recorded at fair value. Changes in fair values of these financial derivative instruments are either recognized in other comprehensive income or net income depending on whether the derivative has been designated and qualifies as a hedging instrument. Interest rate swap agreements. During 2016, the Company entered into an interest rate swap agreement. The interest rate swap agreement, at its inception, qualified for and were designated as cash flow hedging instrument. In accordance with the Derivatives and Hedging Topic of the Accounting Standards Codification, the Company records its interest rate swaps on its consolidated balance sheet at fair value. The effective portion of changes in fair value are recorded in accumulated other comprehensive loss and are subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings. Any ineffective portion is recognized in earnings. Both at inception and on a quarterly basis, the Company performs an effectiveness test.
Debt	Debt. The Company has entered into a Credit Agreement which provides for (a) a five -year revolving credit facility and (b) a five -year term loan facility (Facilities). The amount borrowed under these facilities is recorded at its carrying value at December 31, 2017 . The fair value at December 31, 2017 approximates the carrying value.
Accounts receivable and notes receivable from investment in sales-type leases	Allowance for doubtful accounts and notes receivables from investment in sales-types leases The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. The Company records a specific allowance based on an analysis of individual past-due balances. Additionally, based on historical write-offs and the Company's collection experience, the Company records an additional allowance based on a percentage of outstanding receivables. The Company performs credit evaluations of its customers' financial condition. These evaluations require significant judgment and are based on a variety of factors including, but not limited to, current economic trends, payment history and a financial review of the customer. Actual collection losses may differ from management's estimates, and such differences could be material to the Company's financial position and results of operations. There were no customers that accounted for more than 10% of the Company’s accounts receivable balance as of December 31, 2017 and December 31, 2016 . The retained in-house leases discussed above are considered financing receivables. The Company's credit policies and its evaluation of credit risk and write-off policies are applied alike to trade receivables and the net investment in sales-type leases. For both, an account is generally past due after thirty days. The financing receivables also have customer-specific reserves for accounts identified for specific impairment and a non-specific reserve applied to the remaining population, based on factors such as current trends, the length of time the receivables are past due and historical collection experience. The retained in-house leases are not stratified by portfolio or class.
Sales of accounts receivable	Sales of accounts receivable The Company records the sale of its accounts receivables as in accordance with accounting guidance for transfers and servicing of financial assets.
Inventory	Inventory Inventories are stated at the lower of cost, computed using the first-in, first-out method, and net realizable value. Inbound shipping costs are included in cost of inventory. The Company regularly monitors inventory quantities on hand and records write-downs for excess and obsolete inventories based on the Company's estimate of demand for its products, potential obsolescence of technology, product life cycles, and whether pricing trends or forecasts indicate that the carrying value of inventory exceeds its estimated selling price. These factors are impacted by market and economic conditions, technology changes, and new product introductions and require estimates that may include elements that are uncertain. Actual demand may differ from forecasted demand and may have a material effect on gross margins. If inventory is written down, a new cost basis is established that cannot be increased in future periods. Shipments from suppliers or contract manufacturers before the Company receives them are recorded as in-transit inventory when title and the significant risks and rewards of ownership have passed to the Company.
Property and equipment	Property and equipment Property and equipment less accumulated depreciation are stated at historical cost. The Company's expenditures for property and equipment are primarily for computer equipment and software used in the administration of its business, and for leasehold improvements to its leased facilities. The Company also develops molds and dies used in long-term manufacturing arrangements with suppliers and for production automation equipment used in the manufacturing of consumable blister card components. Depreciation and amortization is computed by use of the straight-line method over the estimated useful lives of the assets as stated below: Computer equipment and related software 3 - 5 years Leasehold and building improvements Shorter of the lease term or the estimated useful life Furniture and fixtures 5 - 7 years Equipment 3 - 12 years Depreciation and amortization of property and equipment was $16.2 million , $15.0 million and $12.8 million for the years ended December 31, 2017 , December 31, 2016 and December 31, 2015 , respectively. The Company capitalizes costs related to computer software developed or obtained for internal use in accordance with ASC 350-40, Internal-Use Software . Software obtained for internal use has generally been enterprise-level business and finance software that the Company customizes to meet its specific operational needs. Costs incurred in the application development phase are capitalized and amortized over their useful lives, which is generally five years. Costs recognized in the preliminary project phase and the post-implementation phase are expensed as incurred.
Software development costs	Software development costs The Company capitalizes software development costs in accordance with ASC 985-20, Costs of Software to Be Sold, Leased, or Marketed , under which certain software development costs incurred subsequent to the establishment of technological feasibility may be capitalized and amortized over the estimated lives of the related products. The Company establishes feasibility when it completes a working model and amortizes development costs over the estimated lives of the related products ranging from three to five years. The Company capitalized software development costs of $15.0 million and $14.3 million which are included in other assets as of December 31, 2017 and December 31, 2016 , respectively. The Company recorded $9.7 million , $7.1 million and $5.8 million to cost of revenues for amortization of capitalized software development costs for the years ended December 31, 2017 , December 31, 2016 and December 31, 2015 , respectively. All development costs prior to the completion of a working model are recognized as research and development expense.
Deferred revenue	Deferred revenue Deferred revenue arise when customers have been billed and/or have received products and/or services in advance of revenue recognition. The Company's deferred revenue, net, presented as short term consists of (i) unearned revenue on sale of equipment for which installation has not been completed, net of deferred cost of sales for such equipment, and (ii) the current portion of unearned service contracts for which revenue is recognized over their duration. Long-term deferred revenue includes long term portion of unearned service contracts.
Business combinations	Business combinations The Company uses the acquisition method of accounting under the authoritative guidance on business combinations. Each acquired company’s operating results are included in the Company's Consolidated Financial Statements starting on the date of acquisition. The purchase price is equivalent to the fair value of consideration transferred. Tangible and identifiable intangible assets acquired and liabilities assumed as of the date of acquisition are recorded at the acquisition date fair value. Goodwill is recognized for the excess of purchase price over the net fair value of assets acquired and liabilities assumed. Amounts allocated to assets and liabilities are based upon fair values. Such valuations require management to make significant estimates and assumptions, especially with respect to the identifiable intangible assets. Management makes estimates of fair value based upon assumptions believed to be reasonable and that of a market participant. These estimates are based on historical experience and information obtained from the management of the acquired companies and the estimates are inherently uncertain. The separately identifiable intangible assets generally include customer relationships, technology, and trade names.
Goodwill and intangible assets	Goodwill and acquired intangible assets Goodwill. The Company reviews goodwill for impairment on an annual basis on the first day of the fourth quarter of each year at the reporting unit level. The Company's reporting units are the same as its operating segments, which are Automation and Analytics and Medication Adherence. A qualitative assessment is initially made to determine whether it is necessary to perform quantitative testing. A qualitative assessment includes, among others, consideration of: (i) past, current and projected future earnings and equity; (ii) recent trends and market conditions; and (iii) valuation metrics involving similar companies that are publicly-traded and acquisitions of similar companies, if available. If this qualitative assessment indicates that it is more likely than not that impairment exists, or if the Company decides to bypass this option, it proceeds to the quantitative assessment. The quantitative assessment involves a comparison between the estimated fair values of the Company's reporting units with their respective carrying amounts including goodwill. If the carrying value exceeds estimated fair value, the Company will record an impairment charge based on that difference. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. To determine each reporting unit's fair value under the quantitative approach, the Company uses a combination of income and market approaches, equally weighting the two approaches, such as estimated discounted future cash flows of that reporting unit, multiples of earnings or revenues, and analysis of recent sales or offerings of comparable entities. The Company also considers its market capitalization on the date of the analysis to ensure the reasonableness of the sum of its reporting units’ fair value. The Company performed a quantitative impairment analysis as of October 1, 2017 for its Medication Adherence reporting unit. The Company determined that the fair value of this reporting unit exceeded the carrying value by more than 40%, and thus no impairment was indicated. Additionally, the Company performed a qualitative impairment assessment analysis as of October 1, 2017 for its Automation and Analytics reporting unit taking into consideration past, current and projected future earnings, recent trends and market conditions; and valuation metrics involving similar companies that are publicly-traded. Based on the result of this analysis an impairment does not exist as of December 31, 2017. Intangible assets. In connection with the Company's acquisitions, it generally recognizes assets for customer relationships, backlog, developed technology, and trade names. Intangible assets are carried at cost less accumulated amortization. Such amortization is provided on a straight-line basis or on an accelerated basis based on a pattern of economic benefit that is expected to be obtained over the estimated useful lives of the respective assets, generally from one to 30 years. Amortization for developed technology and backlog is recognized in cost of revenues, and amortization for customer relationships, non-compete agreements, and trade names is recognized in selling, general and administrative expenses. The Company assesses the impairment of identifiable intangible assets whenever events or changes in circumstances indicate that an asset's carrying amount may not be recoverable. Recoverability of an asset is measured by the comparison of the carrying amount to the sum of the undiscounted estimated future cash flows the asset is expected to generate, offset by estimated future costs to dispose of the product to which the asset relates. If an asset is considered to be impaired, the amount of such impairment would be measured as the difference between the carrying amount of the asset and its fair value. The Company's cash flow assumptions are based on historical and forecasted future revenue, operating costs, and other relevant factors. Assumptions and estimates about the remaining useful lives of the Company's intangible assets are subjective and are affected by changes to its business strategies. If management’s estimates of future operating results change, or if there are changes to other assumptions, the estimate of the fair value of the Company's assets could change significantly. Such change could result in impairment charges in future periods, which could have a significant impact on the Company's operating results and financial condition.
Valuation of share-based awards	Valuation of share-based awards The Company accounts for share-based compensation in accordance with ASC 718, Stock Compensation ("ASC 718"). The Company recognizes compensation expense related to stock-based compensation based on the grant date estimated fair value. The fair value of stock options ("options") on the grant date is estimated using the Black-Scholes option pricing model, which requires the following inputs: expected life, expected volatility, risk-free interest rate, expected dividend yield rate, exercise price, and closing price of its common stock on the date of grant. The expected volatility is based on a combination of historical and market-based implied volatility, and the expected life of the awards is based on the Company's historical experience of employee stock option exercises, including forfeitures. Expense is recognized on a straight-line basis over the requisite service period. The fair value of Restricted Stock Units ("RSUs") is based on the stock price on the grant date. The fair value of Restricted Stock Awards (“RSAs”) is their intrinsic value, which is the difference between the fair value of the underlying stock at the measurement date and the purchase price. The RSUs and RSAs are subject to a service vesting condition and are recognized on a straight-line basis over the requisite service period. The fair value of PSUs with service and market conditions is estimated using a Monte Carlo simulation model applying multiple awards approach. Expense is recognized when it is probable that the performance condition will be met using the accelerated attribution method over the requisite service period. The valuation assumptions used in estimating the fair value of employee share-based awards may change in future periods.
Accounting for income tax	Accounting for income taxes The Company records an income tax provision for (benefit from) the anticipated tax consequences of the reported results of operations. In accordance with U.S. GAAP, the provision for (benefit from) income taxes is computed using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities and for operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using the enacted tax rates in effect for the periods in which those tax assets and liabilities are expected to be realized or settled. In the event that these tax rates change, the Company will incur a benefit or detriment on its income tax expense in the period of change. If the Company were to determine that all or part of the net deferred tax assets are not realizable in the future, it will record a valuation allowance that would be charged to earnings in the period such determination is made. In accordance with ASC 740, Income Taxes, the Company recognizes the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The calculation of tax liabilities involves significant judgment in estimating the impact of uncertainties in the application of U.S. GAAP and complex tax laws. Resolution of these uncertainties in a manner inconsistent with management’s expectations could have a material impact on the Company's financial condition and operating results.
Commissions	Commissions Sales commissions are incremental and directly related to customer sales contracts in which revenue is deferred. These commission costs are accrued and recorded in prepaid expenses upon execution of a non-cancelable customer contract and subsequently expensed in the period of revenue recognition.
Shipping costs	Shipping costs Outbound freight billed to customers is recorded as product revenue. The related shipping and handling costs are expensed as part of selling, general and administrative expense.
Recently adopted accounting standards and recently issued authoritative guidance	Recently adopted accounting standards In March 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718) . This ASU simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The provision of ASU No. 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company adopted the standard effective January 1, 2017. The impact of adoption was the recording of excess tax benefits within income tax expense, rather than in Additional Paid in Capital of $6.6 million for the year ended December 31, 2017. Additionally, in the first quarter of 2017, the Company recognized the previously unrecognized excess tax benefits using the modified retrospective transition method, which resulted in a cumulative-effect adjustment of $1.6 million to retained earnings. In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment , which simplifies the accounting for goodwill impairment for all entities by requiring impairment charges to be based on the first step in today’s two-step impairment test under ASC 350, “Intangibles-Goodwill and Other.” Under the new guidance, if a reporting unit’s carrying amount exceeds its fair value, an entity will record an impairment charge based on that difference. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. ASU 2017-04 is effective for annual and interim impairment tests performed in periods beginning after December 15, 2019. Early adoption is permitted for annual and interim goodwill impairment testing dates after January 1, 2017. The Company adopted ASU 2017-04 effective January 1, 2017. The adoption of this authoritative guidance did not have impact on the Company's Consolidated Financial Statements or related disclosures for the periods presented. In January 2017, the FASB issued ASU 2017-01, Business Combinations , which clarifies the definition of a business and provides a screen to determine when a set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017, with early adoption permitted. The Company adopted ASU 2017-01 effective January 1, 2017. The adoption of this authoritative guidance did not have impact on the Company's Consolidated Financial Statements or related disclosures for the periods presented. In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815) , which simplifies the application of the hedge accounting guidance and improves the financial reporting, specifically simplifies designation and measurement for qualifying hedging relationships and the presentation of hedge results. ASU 2017-12 is effective for annual periods beginning after December 15, 2018 and interim periods within those annual periods with early adoption permitted. The Company adopted ASU 2017-12 effective August 1, 2017. The adoption of this authoritative guidance did not have impact on the Company's Consolidated Financial Statements or related disclosures for the periods presented. Recently issued authoritative guidance In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers ("ASU 2014-09") related to revenue recognition. Under the standard, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The standard will be effective for the Company beginning January 1, 2018. The guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (modified retrospective method). The Company will adopt the standard using the full retrospective method to adjust each prior reporting period presented in the footnote disclosures to the Consolidated Financial Statements. In preparation for adoption of the standard, the Company has implemented functionality changes in the revenue system and internal controls related to new standard adoption to enable the preparation, and reporting and disclosures of the financial information in accordance with the new standard upon the adoption and in future periods. The most significant impact of the standard relates to accounting for direct incremental contract acquisition costs, such as commission expense, term software license revenue and accounting for contingent revenue. The Company currently records the full commission expense in the consolidated statements of operations when commissions are both earned and revenue is recorded. The new revenue standard requires the Company to recognize incremental costs incurred to obtain a contract on a systematic basis that is consistent with the transfer to the customer of the product and services to which the cost relates, including an estimate of the period of service renewals for the transaction. The allocation of the costs between product and service and the estimation of a customer’s services period are management estimates and are based on the Company's historical experience. The Company will allocate commission costs between product and service revenue elements and recognize those when product revenue is recognized and over the estimated service period of 10 years, respectively. The Company expects that the impact of capitalized commissions will be approximately $19 million to $20 million as of December 31, 2017 will be recognized in sales and marketing expense in future periods. The Company expects to recognize the majority of revenue on term software licenses upon installation of the license rather than ratably over the life of the term license. The adoption of the standard will result in an increase in revenue of less than $2 million in 2016 and 2017 and a decrease in deferred revenue of less than $3 million as of December 31, 2017. The new standard no longer requires deferral of contingent revenue in transactions where the amount charged to the customer for a particular performance obligation is less than the allocation of standalone selling price which will result in earlier recognition of revenue. The Company is finalizing the impact on revenue, unbilled accounts receivable and deferred revenue of this adoption adjustment. The Company is currently finalizing the impact on tax expense and deferred taxes of these adoption adjustments. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) . The FASB amended lease accounting requirements to begin recording assets and liabilities arising from most leases on the balance sheet. The new guidance will also require significant additional disclosures about the amount and timing of cash flows from leases. This new guidance will be effective for us beginning on January 1, 2019 using a modified retrospective approach. The modified retrospective approach includes a number of optional practical expedients that entities may elect to apply. The Company is currently evaluating the impact ASU 2016-02 will have on its consolidated financial statements. In October 2016, the FASB issued ASU No. 2016-16 , Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory, which reduces the complexity in the accounting standards by allowing the recognition of current and deferred income taxes for an intra-entity asset transfer, other than inventory, when the transfer occurs. Historically, recognition of the income tax consequence was not recognized until the asset was sold to an outside party. This amendment should be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. ASU 2016-16 is effective for annual periods beginning after December 15, 2017, including interim reporting periods within those annual reporting periods. The Company does not expect application of the amended guidance to have a material effect on its consolidated financial statements. There was no other recently issued and effective authoritative guidance that is expected to have a material impact on the Company's Consolidated Financial Statements through the reporting date.
Fair value hierarchy	Fair value hierarchy The Company measures its financial instruments at fair value. The Company’s cash equivalents are classified within Level 1 of the fair value hierarchy as they are valued primarily using quoted market prices utilizing market observable inputs. The Company's interest rate swap contracts and foreign currency contracts are classified within Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments.
Guarantees	Guarantees As permitted under Delaware law and the Company's certificate of incorporation and bylaws, the Company has agreed to indemnify its directors and officers against certain losses that they may suffer by reason of the fact that such persons are, were or become its directors or officers. The term of the indemnification period is for the director’s or officer’s lifetime and there is no limit on the potential amount of future payments that the Company could be required to make under these indemnification agreements. The Company has purchased a directors’ and officers’ liability insurance policy that may enable it to recover a portion of any future payments that it may be required to make under these indemnification agreements. Assuming the applicability of coverage and the willingness of the insurer to assume coverage and subject to certain retention, loss limits and other policy provisions, the Company believes it is unlikely that the Company will be required to pay any material amounts pursuant to these indemnification obligations. However, no assurances can be given that the insurers will not attempt to dispute the validity, applicability or amount of coverage without expensive and time-consuming litigation against the insurers. Additionally, the Company undertakes indemnification obligations in its ordinary course of business in connection with, among other things, the licensing of its products and the provision of its support services. In the ordinary course of the Company's business, the Company has in the past and may in the future agree to indemnify another party, generally its business affiliates or customers, against certain losses suffered or incurred by the indemnified party in connection with various types of claims, which may include, without limitation, claims of intellectual property infringement, certain tax liabilities, its gross negligence or intentional acts in the performance of support services and violations of laws. The term of these indemnification obligations is generally perpetual. In general, the Company attempts to limit the maximum potential amount of future payments that it may be required to make under these indemnification obligations to the amounts paid to it by a customer, but in some cases the obligation may not be so limited. In addition, the Company has in the past and may in the future warrant to its customers that its products will conform to functional specifications for a limited period of time following the date of installation (generally not exceeding 30 days) or that its software media is free from material defects. Sales contracts for certain of the Company's medication packaging systems often include limited warranties for up to six months, but the periodic activity and ending warranty balances the Company records have historically been immaterial. From time to time, the Company may also warrant that its professional services will be performed in a good and workmanlike manner or in a professional manner consistent with industry standards. The Company generally seeks to disclaim most warranties, including any implied or statutory warranties such as warranties of merchantability, fitness for a particular purpose, title, quality and non-infringement, as well as any liability with respect to incidental, consequential, special, exemplary, punitive or similar damages. In some states, such disclaimers may not be enforceable. If necessary, the Company would provide for the estimated cost of product and service warranties based on specific warranty claims and claim history. The Company has not been subject to any significant claims for such losses and has not incurred any material costs in defending or settling claims related to these indemnification obligations.

Organization and Summary of S26

Organization and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Property and Equipment	Depreciation and amortization is computed by use of the straight-line method over the estimated useful lives of the assets as stated below: Computer equipment and related software 3 - 5 years Leasehold and building improvements Shorter of the lease term or the estimated useful life Furniture and fixtures 5 - 7 years Equipment 3 - 12 years

Business Combinations (Tables)

Business Combinations (Tables)	12 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table represents the allocation of the purchase price to the assets acquired and the liabilities assumed by the Company during each acquisition, respectively, reconciled to the purchase price transferred included in the Company's Consolidated Balance Sheet: Aesynt Ateb Total (In thousands) Cash $ 8,164 $ 902 $ 9,066 Accounts receivable 43,312 7,761 51,073 Inventory 19,021 225 19,246 Other current assets 3,787 1,239 5,026 Total current assets 74,284 10,127 84,411 Property and equipment 10,389 2,447 12,836 Intangible assets 123,700 12,500 136,200 Goodwill 163,599 24,232 187,831 Other non-current assets 968 334 1,302 Total assets 372,940 49,640 422,580 Current liabilities 26,753 4,895 31,648 Deferred revenue, net 25,512 2,776 28,288 Non-current deferred tax liabilities 38,622 — 38,622 Other non-current liabilities 2,431 367 2,798 Total liabilities 93,318 8,038 101,356 Total purchase price 279,622 41,602 321,224 Total purchase price, net of cash received $ 271,458 $ 40,700 $ 312,158
Intangible Assets Acquired	The identifiable intangible assets acquired and their estimated useful lives for amortization are as follows: Aesynt Ateb Fair value Weighted Fair value Weighted (In thousands) (In years) (In thousands) (In years) Customer relationships $ 58,200 14-16 $ 8,900 12 Developed technology 38,800 8 3,400 5 Backlog 20,200 1-3 — - In-process research and development ("IPR&D") (1) 3,900 - — - Non-compete 1,800 3 100 1 Trade names 800 1 100 1 Total purchased intangible assets $ 123,700 $ 12,500 (1) The amortization of the in-process R&D assets begins when the in-process R&D projects are complete.
Business Acquisition, Pro Forma Information	The pro forma adjustments include the impact of fair value adjustment related to deferred revenue, inventory fair value adjustment, amortization of intangible assets, stock-based compensation expense, interest expense and amortization of deferred issuance cost, and certain classification to conform to the Company's accounting policies. Twelve months ended December 31, 2017 2016 2015 (in thousands, except per share data) Pro forma net revenues $ 716,723 $ 719,799 $ 523,241 Pro forma net income (loss) $ 20,770 $ (1,044 ) $ 2,245 Pro forma net income (loss) per share $ 0.54 $ (0.03 ) $ 0.06 Weighted average number of shares 38,712 36,156 36,699

Net Income Per Share (Tables)

Net Income Per Share (Tables)	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Basic and Diluted Net Income Per Share	The calculation of basic and diluted net income per share is as follows: Year Ended December 31, 2017 2016 2015 (In thousands, except per share data) Net income $ 20,605 $ 603 $ 30,760 Weighted-average shares outstanding — basic 37,483 36,156 35,857 Add: Dilutive effect of employee stock plans 1,229 708 861 Weighted-average shares outstanding — diluted 38,712 36,864 36,718 Net income per share — basic $ 0.55 $ 0.02 $ 0.86 Net income per share — diluted $ 0.53 $ 0.02 $ 0.84 Anti-dilutive weighted-average shares related to stock award plans 501 1,345 555

Cash and Cash Equivalents and29

Cash and Cash Equivalents and Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Schedule of Financial Assets Measured at Fair Value	The following table represents the fair value hierarchy of the Company’s financial assets measured at fair value as of December 31, 2017 : Level 1 Level 2 Level 3 Total (In thousands) Interest rate swap contracts $ — $ 1,378 $ — $ 1,378 Total financial assets $ — $ 1,378 $ — $ 1,378 The following table represents the fair value hierarchy of the Company’s financial assets measured at fair value as of December 31, 2016 : Level 1 Level 2 Level 3 Total (In thousands) Interest rate swap contracts $ — $ 1,245 $ — $ 1,245 Total financial assets $ — $ 1,245 $ — $ 1,245 Contingent consideration liability — — 2,400 2,400 Total financial liabilities $ — $ — $ 2,400 $ 2,400

Balance Sheet Components (Table

Balance Sheet Components (Tables)	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Balance Sheet	Balance sheet details as of December 31, 2017 and December 31, 2016 are presented in the tables below: December 31, 2017 2016 (In thousands) Inventories: Raw materials $ 22,750 $ 14,322 Work in process 9,818 7,800 Finished goods 63,569 47,175 Total inventories $ 96,137 $ 69,297 Prepaid expenses Prepaid commissions $ 15,671 $ 13,176 Other prepaid expenses 20,389 15,470 Total prepaid expense $ 36,060 $ 28,646 Property and equipment: Equipment $ 69,550 $ 64,384 Furniture and fixtures 6,534 6,517 Leasehold improvements 10,976 9,778 Software 37,168 35,607 Construction in progress 9,813 7,211 Property and equipment, gross 134,041 123,497 Accumulated depreciation and amortization (91,446 ) (81,486 ) Total property and equipment, net $ 42,595 $ 42,011 Other long term assets: Capitalized software, net $ 38,599 $ 33,233 Other assets 1,242 1,818 Total other long term assets, net $ 39,841 $ 35,051 Accrued liabilities: Advance payments from customers $ 7,779 $ 7,030 Rebates and lease buyouts 5,428 4,025 Group purchasing organization fees 3,449 3,737 Taxes payable 9,183 4,003 Other accrued liabilities 9,854 12,400 Total accrued liabilities $ 35,693 $ 31,195
Schedule of Accumulated Other Comprehensive Income	The following table summarizes the changes in accumulated balances of other comprehensive income (loss) for the years ended December 31, 2017 and December 31, 2016 : Foreign currency translation adjustments Unrealized gain (loss) on interest rate swap hedges Total (In thousands) Balance as of December 31, 2015 $ (2,730 ) $ — $ (2,730 ) Other comprehensive income (loss) before reclassifications (8,034 ) 1,385 (6,649 ) Amounts reclassified from other comprehensive income (loss) — (140 ) (140 ) Net current-period other comprehensive income (loss), net of tax (8,034 ) 1,245 (6,789 ) Balance as of December 31, 2016 (10,764 ) 1,245 (9,519 ) Other comprehensive income (loss) before reclassifications 3,810 409 4,219 Amounts reclassified from other comprehensive income (loss), net of tax — (813 ) (813 ) Net current-period other comprehensive income (loss), net of tax 3,810 (404 ) 3,406 Balance as of December 31, 2017 $ (6,954 ) $ 841 $ (6,113 )

Net Investment in Sales-Type 31

Net Investment in Sales-Type Leases (Tables)	12 Months Ended
	Dec. 31, 2017
Leases [Abstract]
Schedule of Long Term Net Investment in Sale-Type Leases	The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at December 31, 2017 and December 31, 2016 : December 31, 2017 2016 (In thousands) Net minimum lease payments to be received $ 25,899 $ 33,591 Less: unearned interest income portion (1,695 ) (2,763 ) Net investment in sales-type leases 24,204 30,828 Less: short-term portion (1) (8,769 ) (10,243 ) Long-term net investment in sales-type leases $ 15,435 $ 20,585 (1) The short-term portion of the net investments in sales-type leases is included in the other current assets on the Consolidated Balance Sheets.
Schedule of Financing Receivables, Minimum Payments	At December 31, 2017 , the future minimum lease payments to be received under sales-type leases are as follows: Year ended December 31, (In thousands) 2018 $ 8,769 2019 6,708 2020 4,772 2021 2,992 2022 2,265 Thereafter 393 Total $ 25,899

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Carrying Amount of Goodwill	The changes in the carrying amount of goodwill are as follows: Automation and Analytics Medication Adherence Total (In thousands) Net balance as of December 31, 2015 $ 54,316 $ 93,590 $ 147,906 Additions (1) 163,599 20,832 184,431 Adjustments (2) (2,833 ) (1,780 ) (4,613 ) Net balance as of December 31, 2016 215,082 112,642 327,724 Additions (3) 3,113 3,400 6,513 Adjustments (2) 2,656 858 3,514 Net balance as of December 31, 2017 $ 220,851 $ 116,900 $ 337,751 _________________________________________________ (1) Additions to goodwill as a result of the Aesynt acquisition in January 2016 and Ateb acquisition in December 2016. (2) Adjustments reflect foreign currency exchange rate fluctuations. (3) Additions to goodwill in Automation and Analytics segment was a result of the InPharmics acquisition in April 2017. Additions to goodwill in Medication Adherence segment represent adjustments to the preliminary value assigned to goodwill in connection with Ateb acquisition to reflect measurement period adjustments related to accounts receivable, other non-current assets and other liabilities of $0.1 million , $0.7 million and $2.6 million , respectively.
Intangible Assets, Net	The carrying amounts of intangible assets and useful lives as of December 31, 2017 were as follows: December 31, 2017 Gross carrying amount Accumulated amortization Foreign currency exchange rate fluctuations Net carrying amount Useful life (years) (In thousands, except for years) Customer relationships $ 133,913 $ (33,526 ) $ 65 $ 100,452 1 - 30 Acquired technology 74,593 (21,523 ) 34 53,104 3 - 20 Backlog 21,712 (17,544 ) — 4,168 1 - 4 Trade names 8,716 (4,719 ) 6 4,003 1 - 12 Patents 3,296 (1,418 ) 2 1,880 2 - 20 Non-compete agreements 1,900 (1,300 ) — 600 3 In process technology 3,900 — — 3,900 - Total intangibles assets, net $ 248,030 $ (80,030 ) $ 107 $ 168,107 The carrying amounts of intangible assets and useful lives as of December 31, 2016 were as follows: December 31, 2016 Gross carrying amount Accumulated amortization Foreign currency exchange rate fluctuations Net carrying amount Useful life (years) (In thousands, except for years) Customer relationships $ 133,358 $ (20,930 ) $ (596 ) $ 111,832 1 - 30 Acquired technology 73,599 (13,287 ) (159 ) 60,153 3 - 20 Backlog 20,550 (14,083 ) — 6,467 1 - 3 Trade names 8,667 (3,887 ) (31 ) 4,749 1 - 12 Patents 3,154 (1,264 ) — 1,890 2 - 20 Non-compete agreements 1,900 (608 ) — 1,292 3 In-process technology 3,900 — — 3,900 - Total intangibles assets, net $ 245,128 $ (54,059 ) $ (786 ) $ 190,283
Future Amortization Expense for Intangible Assets	The estimated future amortization expenses for intangible assets are as follows: For the year ended December 31, (In thousands) 2018 $ 23,433 2019 17,953 2020 16,739 2021 15,439 2022 13,973 Thereafter (excluding in-process technology) 76,670 Total $ 164,207

Debt and Credit Agreement (Tabl

Debt and Credit Agreement (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	The components of the Company’s debt obligations as of December 31, 2017 and December 31, 2016 are as follows: December 31, 2016 Additions/Borrowings Repayment / Amortization December 31, 2017 (In thousands) Term loan facility $ 192,500 $ — $ (10,000 ) $ 182,500 Revolving credit facility 68,000 59,000 (92,500 ) 34,500 Total debt under the facilities 260,500 59,000 (102,500 ) 217,000 Less: Deferred issuance cost (6,359 ) (2,106 ) 1,590 (6,875 ) Total Debt, net of deferred issuance cost $ 254,141 $ 56,894 $ (100,910 ) $ 210,125 Long term debt, current portion, net of deferred issuance cost 8,410 15,208 Long term debt, net of deferred issuance cost $ 245,731 $ 194,917

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Minimum Future Rental on Non-Cancelable Operating Leases	The minimum future payments on non-cancelable operating leases are as follows: For the year ended December 31, (In thousands) 2018 $ 12,167 2019 11,945 2020 10,755 2021 10,471 2022 8,776 Thereafter 26,243 Total minimum future lease payments $ 80,357

Employee Benefits and Share-B35

Employee Benefits and Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation Expense Recognized in Consolidate Statements of Income	The following table sets forth the total share-based compensation expense recognized in the Company's Consolidated Statements of Operations: Year Ended December 31, 2017 2016 2015 (In thousands) Cost of product and service revenues $ 3,478 $ 2,596 $ 2,111 Research and development 3,590 3,128 2,060 Selling, general and administrative 14,789 13,776 10,750 Total share-based compensation expense $ 21,857 $ 19,500 $ 14,921
Estimate of Fair Value of Share-Based Awards, Stock Options	The following assumptions were used to value share options and ESPP shares granted pursuant to our equity incentive plans: Year Ended December 31, 2017 2016 2015 Stock Option Plans Risk-free interest rate 1.9 % 1.5 % 1.7 % Dividend yield — % — % — % Expected volatility 29.6 % 30.6 % 32.0 % Expected life (in years) 4.7 years 4.9 years 5.0 years
Estimate of Fair Value of Share-Based Awards, Employee Stock Purchase Plan	Year Ended December 31, 2017 2016 2015 Employee Stock Purchase Plan Risk-free interest rate 0.52% - 1.39% 0.34% - 0.79% 0.03% - 0.79% Dividend yield — % — % — % Expected volatility 25.8% - 32.8% 25.8% - 34.8% 25.7% - 37.5% Expected life (in years) 0.5 - 2.0 0.5 - 2.0 0.5 - 2.0
Stock Option Activity under the 2009 Plan	A summary of the stock option activity under the 2009 Plan is presented below: Number of Shares Weighted-Average Exercise Price Weighted-Average Remaining Years Aggregate Intrinsic Value (In thousands, except per share data) Outstanding at December 31, 2016 3,214 $ 26.06 7.3 $ 26,331 Granted (Awarded) 1,045 $ 45.13 Exercised (Released) (813 ) $ 22.28 Expired (6 ) $ 27.54 Forfeited (117 ) $ 33.39 Outstanding at December 31, 2017 3,323 32.72 7.6 $ 53,953 Exercisable at December 31, 2017 1,350 23.87 5.8 33,293 Vested and expected to vest at December 31, 2017 and thereafter 3,323 32.72 7.6 $ 53,953
Restricted Stock Units Activity under the 2009 Plan	Summaries of the restricted stock activity under the 2009 Plan are presented below: Number of Shares Weighted-Average Grant Date Fair Value Weighted-Average Remaining Years Aggregate Intrinsic Value (In thousands, except per share data) Restricted Stock Units Non-vested at December 31, 2016 505 $ 31.42 1.6 $ 17,135 Granted (Awarded) 245 45.97 Vested (Released) (215 ) 30.41 Forfeited (34 ) 32.39 Non-vested at December 31, 2017 501 38.90 1.5 $ 24,293
Restricted Stock Awards under the 2009 Plan	Number of Shares Weighted-Average Grant Date Fair Value (In thousands, except per share data) Restricted Stock Awards Non-vested at December 31, 2016 30 $ 31.57 Granted (Awarded) 23 41.10 Vested (Released) (30 ) 31.58 Non-vested at December 31, 2017 23 $ 41.07
Performance Shares Restricted Stock Activity under the 2009 Plan	A summary of the performance-based restricted stock activity under the 2009 Plan is presented below: Number of Shares Weighted-Average Grant Date Fair Value Per Unit (In thousands, except per share data) Non-vested at December 31, 2016 184 $ 24.89 Granted (Awarded) 148 34.05 Vested (Released) (107 ) 24.36 Non-vested at December 31, 2017 225 $ 31.18
Schedule of Share-based Compensation, Future Issuance of Shares	The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of December 31, 2017 : Number of Shares (In thousands) Share options outstanding 3,323 Non-vested restricted stock awards 749 Shares authorized for future issuance 1,398 ESPP shares available for future issuance 2,365 Total shares reserved for future issuance 7,835

Segment and Geographical Info36

Segment and Geographical Information (Tables)	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Financial Performance of Reporting Segments	The following table summarizes the financial performance of the Company's reporting segments: Year Ended December 31, 2017 2016 2015 Automation and Analytics Medication Total Automation and Analytics Medication Adherence Total Automation and Analytics Medication Adherence Total (In thousands) Revenues $ 590,392 $ 125,773 $ 716,165 $ 593,626 $ 98,997 $ 692,623 $ 390,321 $ 94,238 $ 484,559 Cost of revenues 308,443 85,634 394,077 310,967 67,856 378,823 171,943 64,686 236,629 Gross profit 281,949 40,139 322,088 282,659 31,141 313,800 218,378 29,552 247,930 Operating expenses 193,700 41,735 235,435 198,511 24,843 223,354 114,084 24,258 138,342 Income from operations $ 88,249 $ (1,596 ) 86,653 $ 84,148 $ 6,298 90,446 $ 104,294 $ 5,294 109,588 Corporate costs 80,899 83,965 60,956 Income from operations $ 5,754 $ 6,481 $ 48,632 _________________________________________________
Revenue by Geographical Location	Revenues Year Ended December 31, 2017 2016 2015 (In thousands) United States $ 617,268 $ 591,566 $ 403,375 Rest of world (1) 98,897 101,057 81,184 Total revenues $ 716,165 $ 692,623 $ 484,559 ___________________________________________ (1) No individual country represented more than 10% of the respective totals.
Long-lived Assets by Geographic Areas	Property and equipment, net Property and equipment, net is attributed to the geographic location in which it is located. Year Ended December 31, 2017 2016 2015 (In thousands) United States $ 34,899 $ 36,497 $ 29,506 Rest of world (1) 7,696 5,514 2,803 Total property and equipment, net $ 42,595 $ 42,011 $ 32,309 _________________________________________________ (1) No individual country represented more than 10% of the respective totals.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign	The following is a geographical breakdown of income (loss) before the provision for (benefit from) income taxes: Year Ended December 31, 2017 2016 2015 (In thousands) Domestic $ 19,889 $ 1,471 $ 51,089 Foreign (20,768 ) (3,419 ) (4,845 ) Income (loss) before provision for (benefit from) income taxes $ (879 ) $ (1,948 ) $ 46,244
Schedule of Components of Income Tax Expense (Benefit)	The provision for (benefit from) income taxes consists of the following: Year Ended December 31, 2017 2016 2015 (In thousands) Current: Federal $ 2,430 $ 6,724 $ 13,840 State 1,852 1,323 2,475 Foreign 745 46 203 Total current income taxes 5,027 8,093 16,518 Deferred: Federal (16,118 ) (3,378 ) 846 State (2,612 ) (1,802 ) (379 ) Foreign (7,781 ) (5,464 ) (1,501 ) Total deferred income taxes (26,511 ) (10,644 ) (1,034 ) Total provision for (benefit from) income taxes $ (21,484 ) $ (2,551 ) $ 15,484
Schedule of Effective Income Tax Rate Reconciliation	The provision for (benefit from) income taxes differs from the amount computed by applying the statutory federal tax rate as follows: Year Ended December 31, 2017 2016 2015 (In thousands) U.S. federal tax provision at statutory rate $ (308 ) $ (682 ) $ 16,181 State taxes 19 (311 ) 1,365 Non-deductible expenses 1,373 1,212 551 Acquisition costs — 845 239 Share-based compensation expense 39 1,941 748 Research tax credits (3,233 ) (2,075 ) (1,324 ) Domestic production deduction (621 ) (890 ) (1,133 ) Gain on investment — — (1,205 ) Tax audit settlement — (2,499 ) — Foreign rate differential 938 (154 ) 123 Stock option tax benefit (5,926 ) — — One-time Impact of the Tax Act (13,391 ) — — Other (374 ) 62 (61 ) Total provision for (benefit from) income taxes $ (21,484 ) $ (2,551 ) $ 15,484
Schedule of Deferred Tax Assets and Liabilities	Significant components of the Company's deferred tax assets (liabilities) are as follows: December 31, December 31, (In thousands) Deferred tax assets (liabilities): Deferred revenue $ 6,345 $ 5,857 Stock compensation 4,460 6,451 Inventory related items 2,441 2,915 Tax credit carry forwards 9,349 4,871 Reserves and accruals 3,960 4,675 Loss carry forwards 8,643 8,077 Other, net 1,307 847 Total net deferred tax assets 36,505 33,693 Intangibles (36,780 ) (57,427 ) Depreciation and amortization (14,338 ) (20,071 ) Prepaid expenses (4,512 ) (3,746 ) Total deferred tax liabilities (55,630 ) (81,244 ) Net deferred tax liabilities $ (19,125 ) $ (47,551 )
Schedule of Unrecognized Tax Benefits	The aggregate change in the balance of gross unrecognized tax benefits, which excludes interest and penalties, for the three years ended December 31, 2017 is as follows: (In thousands) Year Ended December 31, 2014 $ 8,485 Increases related to tax positions taken during a prior period 37 Decreases related to tax positions taken during the prior period (895 ) Increases related to tax positions taken during the current period 1,807 Decreases related to settlements — Decreases related to expiration of statute of limitations (284 ) Year Ended December 31, 2015 9,150 Increases related to tax positions taken during a prior period 244 Decreases related to tax positions taken during the prior period (1,980 ) Increases related to tax positions taken during the current period 6,724 Decreases related to settlements (2,178 ) Decreases related to expiration of statute of limitations (344 ) Year Ended December 31, 2016 11,616 Increases related to tax positions taken during a prior period 503 Decreases related to tax positions taken during the prior period (1,782 ) Increases related to tax positions taken during the current period 805 Decreases related to settlements — Decreases related to expiration of statute of limitations (401 ) Year Ended December 31, 2017 $ 10,741

Organization and Summary of S38

Organization and Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2017	Apr. 30, 2015
Accounting Policies [Line Items]
Vendor-Specific Objective Evidence (VSOE) exist when (approximately 80% or more) standalone sales are within a reasonable price range		80.00%
Transferred non-recourse accounts receivables		$ 40,000,000	$ 28,700,000	$ 38,600,000
Accounts receivables from third-party leasing companies for transferred non-recourse accounts receivables		100,000	200,000	800,000
Depreciation and amortization		16,200,000	15,000,000	12,800,000
Commissions expense		19,400,000	22,000,000	13,700,000
Administrative fees		7,400,000	8,400,000	5,900,000
Cumulative effect of a change in accounting principle related to stock-based compensation		1,582,000
Accumulated Earnings (Deficit)
Accounting Policies [Line Items]
Cumulative effect of a change in accounting principle related to stock-based compensation		1,582,000
ASU 2016-09
Accounting Policies [Line Items]
Change in accounting guidance, impact on net income	$ 6,600,000
ASU 2016-09 | Accumulated Earnings (Deficit)
Accounting Policies [Line Items]
Cumulative effect of a change in accounting principle related to stock-based compensation					$ 1,600,000
ASU 2014-09 | Difference between Revenue Guidance in Effect before andafter Topic 606 | Pro Forma | Accumulated Earnings (Deficit)
Accounting Policies [Line Items]
Software revenue		$ (3,000,000)	2,000,000
Internal use software and development costs
Accounting Policies [Line Items]
Useful life (in years)		5 years
Software and development costs to be sold
Accounting Policies [Line Items]
Cost of revenues for amortization of capitalized software development cost		$ 9,700,000	7,100,000	5,800,000
Minimum
Accounting Policies [Line Items]
Vendor-Specific Objective Evidence, within a reasonably narrow price range (plus or minus of median rate)		15.00%
Estimated useful lives of assets (in years)		1 year
Minimum | ASU 2014-09 | Difference between Revenue Guidance in Effect before andafter Topic 606 | Pro Forma | Accumulated Earnings (Deficit)
Accounting Policies [Line Items]
Capitalized commissions		$ 19,000,000
Minimum | Computer Equipment
Accounting Policies [Line Items]
Useful life (in years)		3 years
Minimum | Furniture and Fixtures
Accounting Policies [Line Items]
Useful life (in years)		5 years
Minimum | Equipment
Accounting Policies [Line Items]
Useful life (in years)		3 years
Maximum
Accounting Policies [Line Items]
Vendor-Specific Objective Evidence, within a reasonably narrow price range (plus or minus of median rate)		15.00%
Estimated useful lives of assets (in years)		30 years
Maximum | ASU 2014-09 | Difference between Revenue Guidance in Effect before andafter Topic 606 | Pro Forma | Accumulated Earnings (Deficit)
Accounting Policies [Line Items]
Capitalized commissions		$ 20,000,000
Maximum | Computer Equipment
Accounting Policies [Line Items]
Useful life (in years)		5 years
Maximum | Furniture and Fixtures
Accounting Policies [Line Items]
Useful life (in years)		7 years
Maximum | Equipment
Accounting Policies [Line Items]
Useful life (in years)		12 years
Selling, general and administrative
Accounting Policies [Line Items]
Shipping and handling expenses		$ 13,600,000	12,100,000	8,500,000
Capitalized software costs included in property and equipment | Internal use software and development costs
Accounting Policies [Line Items]
Software development costs capitalized		400,000	2,200,000
Capitalized software costs included in other assets | Software and development costs to be sold
Accounting Policies [Line Items]
Software development costs capitalized		15,000,000	14,300,000
Primary Supplier
Accounting Policies [Line Items]
Minimum supplier purchase obligations		$ 0
Notice of termination, time upon delivery (in months)		2 months
Payments to suppliers		$ 64,500,000	$ 47,900,000	$ 41,700,000
Credit Concentration Risk | Lease Receivable
Accounting Policies [Line Items]
Concentration risk percentage		33.00%
Customer Concentration Risk
Accounting Policies [Line Items]
Concentration risk percentage		51.20%	51.20%	65.20%
Customer Concentration Risk | Sales Revenue, Net
Accounting Policies [Line Items]
Concentration risk percentage		51.20%
Avantec Heathcare Limited
Accounting Policies [Line Items]
Percentage of interest acquired						85.00%
Revolving Credit Facility
Accounting Policies [Line Items]
Debt instrument, term (in years)		5 years
Term Loan Facility
Accounting Policies [Line Items]
Debt instrument, term (in years)		5 years

Business Combinations - Additio

Business Combinations - Additional Information (Details) - USD ($) $ in Thousands	Apr. 12, 2017	Jan. 05, 2016	Dec. 31, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Acquired Finite-Lived Intangible Assets [Line Items]
Purchase price of acquisition				$ 4,446	$ 312,158	$ 25,507
Goodwill			$ 147,906	337,751	327,724	$ 147,906
InPharmics
Acquired Finite-Lived Intangible Assets [Line Items]
Purchase price of acquisition	$ 5,000
Cash consideration	300
Long-term liability for potential settlement of performance obligations	500
Intangibles	$ 1,900
Aesynt Holding, L.P., Aesynt, Ltd.
Acquired Finite-Lived Intangible Assets [Line Items]
Purchase price of acquisition				271,458
Cash consideration				8,164
Intangibles				123,700
Cash acquired from Acquisition				8,200
Goodwill				163,599
Goodwill, purchase accounting adjustments				1,200
Provisional accounting, accounts receivable				1,600
Provisional accounting, inventory				1,100
Provisional accounting, other assets and liabilities				(3,900)
Acquisition related costs		$ 9,300	$ 2,900	6,400
Total purchase price				279,622
Aesynt Holding, L.P., Aesynt, Ltd. | In-process research and development
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value inputs, royalty rate		12.50%
Aesynt Holding, L.P., Aesynt, Ltd. | Developed technology
Acquired Finite-Lived Intangible Assets [Line Items]
Intangibles				38,800
Aesynt Holding, L.P., Aesynt, Ltd. | Trade name
Acquired Finite-Lived Intangible Assets [Line Items]
Intangibles				800
Fair value inputs, royalty rate		0.50%
Aesynt Holding, L.P., Aesynt, Ltd. | Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Intangibles				58,200
Fair value inputs, discount rate		13.00%
Aesynt Holding, L.P., Aesynt, Ltd. | Backlog
Acquired Finite-Lived Intangible Assets [Line Items]
Intangibles				20,200
Fair value inputs, discount rate		10.00%
Aesynt Holding, L.P., Aesynt, Ltd. | Non-compete
Acquired Finite-Lived Intangible Assets [Line Items]
Intangibles				1,800
Fair value inputs, discount rate		13.00%
Aesynt Holding, L.P., Aesynt, Ltd. | Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
IPR&D expected term (in years)		3 years
Aesynt Holding, L.P., Aesynt, Ltd. | Maximum | Developed technology
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value inputs, royalty rate		8.00%
Aesynt Holding, L.P., Aesynt, Ltd. | Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
IPR&D expected term (in years)		2 years
Aesynt Holding, L.P., Aesynt, Ltd. | Minimum | Developed technology
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value inputs, royalty rate		4.00%
Ateb
Acquired Finite-Lived Intangible Assets [Line Items]
Purchase price of acquisition				40,700
Cash consideration				902
Intangibles				12,500
Cash acquired from Acquisition				900
Goodwill				24,232
Goodwill, purchase accounting adjustments				3,400
Provisional accounting, accounts receivable				100
Provisional accounting, inventory				700
Provisional accounting, other assets and liabilities				2,600
Acquisition-related costs					$ 1,700
Total purchase price				41,602
Ateb | Developed technology
Acquired Finite-Lived Intangible Assets [Line Items]
Intangibles				3,400
Ateb | Trade name
Acquired Finite-Lived Intangible Assets [Line Items]
Intangibles				100
Fair value inputs, royalty rate		0.50%
Ateb | Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Intangibles				$ 8,900
Fair value inputs, discount rate				15.00%
Ateb | Non-compete
Acquired Finite-Lived Intangible Assets [Line Items]
Intangibles				$ 100
Fair value inputs, discount rate				15.00%
Ateb | Maximum | Developed technology
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value inputs, royalty rate		6.00%
Ateb | Minimum | Developed technology
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value inputs, royalty rate		5.00%

Business Combinations - Total P

Business Combinations - Total Purchase Price and Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Goodwill	$ 337,751	$ 327,724	$ 147,906
Total purchase price, net of cash received	4,446	$ 312,158	$ 25,507
Aesynt
Business Acquisition [Line Items]
Cash	8,164
Accounts receivable	43,312
Inventory	19,021
Other current assets	3,787
Total current assets	74,284
Property and equipment	10,389
Intangibles	123,700
Goodwill	163,599
Other non-current assets	968
Total assets	372,940
Current liabilities	26,753
Deferred revenue, net	25,512
Long-term deferred tax liabilities	38,622
Other non-current liabilities	2,431
Total liabilities	93,318
Total purchase price	279,622
Total purchase price, net of cash received	271,458
Ateb
Business Acquisition [Line Items]
Cash	902
Accounts receivable	7,761
Inventory	225
Other current assets	1,239
Total current assets	10,127
Property and equipment	2,447
Intangibles	12,500
Goodwill	24,232
Other non-current assets	334
Total assets	49,640
Current liabilities	4,895
Deferred revenue, net	2,776
Long-term deferred tax liabilities	0
Other non-current liabilities	367
Total liabilities	8,038
Total purchase price	41,602
Total purchase price, net of cash received	40,700
Aesynt and Ateb
Business Acquisition [Line Items]
Cash	9,066
Accounts receivable	51,073
Inventory	19,246
Other current assets	5,026
Total current assets	84,411
Property and equipment	12,836
Intangibles	136,200
Goodwill	187,831
Other non-current assets	1,302
Total assets	422,580
Current liabilities	31,648
Deferred revenue, net	28,288
Long-term deferred tax liabilities	38,622
Other non-current liabilities	2,798
Total liabilities	101,356
Total purchase price	321,224
Total purchase price, net of cash received	$ 312,158

Business Combinations - Identif

Business Combinations - Identifiable Intangible Assets (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)
Aesynt
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets	$ 123,700
Aesynt | Customer relationships
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets	$ 58,200
Aesynt | Customer relationships | Minimum
Finite-Lived Intangible Assets [Line Items]
Weighted average useful life (in years)	14 years
Aesynt | Customer relationships | Maximum
Finite-Lived Intangible Assets [Line Items]
Weighted average useful life (in years)	16 years
Aesynt | Developed technology
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets	$ 38,800
Weighted average useful life (in years)	8 years
Aesynt | Backlog
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets	$ 20,200
Aesynt | Backlog | Minimum
Finite-Lived Intangible Assets [Line Items]
Weighted average useful life (in years)	1 year
Aesynt | Backlog | Maximum
Finite-Lived Intangible Assets [Line Items]
Weighted average useful life (in years)	3 years
Aesynt | In-process research and development
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets	$ 3,900
Aesynt | Non-compete
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets	$ 1,800
Weighted average useful life (in years)	3 years
Aesynt | Trade name
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets	$ 800
Weighted average useful life (in years)	1 year
Ateb
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets	$ 12,500
Ateb | Customer relationships
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets	$ 8,900
Weighted average useful life (in years)	12 years
Ateb | Developed technology
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets	$ 3,400
Weighted average useful life (in years)	5 years
Ateb | Non-compete
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets	$ 100
Weighted average useful life (in years)	1 year
Ateb | Trade name
Finite-Lived Intangible Assets [Line Items]
Total purchased intangible assets	$ 100
Weighted average useful life (in years)	1 year

Business Combinations - Pro For

Business Combinations - Pro Forma Information (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Business Combinations [Abstract]
Pro forma net revenues	$ 716,723	$ 719,799	$ 523,241
Pro forma net income (loss)	$ 20,770	$ (1,044)	$ 2,245
Pro forma net income (loss) per share	$ 0.54	$ (0.03)	$ 0.06
Weighted average number of shares	38,712	36,156	36,699

Net Income Per Share (Details)

Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Earnings Per Share [Abstract]
Net income	$ 20,605	$ 603	$ 30,760
Weighted-average shares outstanding — basic	37,483	36,156	35,857
Add: Dilutive effect of employee stock plans	1,229	708	861
Weighted-average shares outstanding — diluted	38,712	36,864	36,718
Net income, basic (usd per share)	$ 0.55	$ 0.02	$ 0.86
Net income, diluted (usd per share)	$ 0.53	$ 0.02	$ 0.84
Anti-dilutive weighted-average shares related to stock award plans	501	1,345	555

Cash and Cash Equivalents and44

Cash and Cash Equivalents and Fair Value of Financial Instruments - Additional Information (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Cash and cash equivalents	$ 32,424	$ 54,488	$ 82,217	$ 125,888

Cash and Cash Equivalents and45

Cash and Cash Equivalents and Fair Value of Financial Instruments - Fair Value Hierarchy (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain related to contingent liability	$ 0	$ 600	$ 0
Avantec Heathcare Limited
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent liability, before payout	3,000
Contingent liability, after payout	2,400
Gain related to contingent liability	$ 600

Cash and Cash Equivalents and46

Cash and Cash Equivalents and Fair Value of Financial Instruments - Financial Assets and Liabilities Measured At Fair Value (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap contracts	$ 1,378	$ 1,245
Total financial assets	1,378	1,245
Total financial liabilities		2,400
Fair Value, Inputs, Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap contracts	0	0
Total financial assets	0	0
Total financial liabilities		0
Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap contracts	1,378	1,245
Total financial assets	1,378	1,245
Total financial liabilities		0
Fair Value, Inputs, Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap contracts	0	0
Total financial assets	$ 0	0
Total financial liabilities		2,400
Contingent consideration liability
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities		2,400
Contingent consideration liability | Fair Value, Inputs, Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities		0
Contingent consideration liability | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities		0
Contingent consideration liability | Fair Value, Inputs, Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities		$ 2,400

Cash and Cash Equivalents and47

Cash and Cash Equivalents and Fair Value of Financial Instruments - Foreign Currency Risk Management (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Derivatives, Fair Value [Line Items]
Interest rate swap contracts	$ 1,378,000	$ 1,245,000
Foreign Exchange Forward
Derivatives, Fair Value [Line Items]
Derivative, notional amount	0	$ 0
Interest Rate Swap
Derivatives, Fair Value [Line Items]
Derivative, notional amount	$ 100,000,000
Derivative, fixed interest rate	0.80%
LIBOR | Interest Rate Swap
Derivatives, Fair Value [Line Items]
Derivative, variable rate floor	0.00%

Cash and Cash Equivalents and48

Cash and Cash Equivalents and Fair Value of Financial Instruments - Interest Rate Swap Contracts (Details) - Interest Rate Swap - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Derivatives, Fair Value [Line Items]
Derivative, notional amount	$ 100
Derivative, fixed interest rate	0.80%
Fair value of derivatives	$ 1.4	$ 1.2
LIBOR
Derivatives, Fair Value [Line Items]
Derivative, variable rate floor	0.00%

Balance Sheet Components (Detai

Balance Sheet Components (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Inventories:
Raw materials	$ 22,750	$ 14,322
Work in process	9,818	7,800
Finished goods	63,569	47,175
Total inventories, net	96,137	69,297
Prepaid expenses
Prepaid commissions	15,671	13,176
Other prepaid expenses	20,389	15,470
Prepaid expenses	36,060	28,646
Property and equipment:
Equipment	69,550	64,384
Furniture and fixtures	6,534	6,517
Leasehold improvements	10,976	9,778
Software	37,168	35,607
Construction in progress	9,813	7,211
Property and equipment, gross	134,041	123,497
Accumulated depreciation and amortization	(91,446)	(81,486)
Total property and equipment, net	42,595	42,011	$ 32,309
Other long term assets:
Capitalized software, net	38,599	33,233
Other assets	1,242	1,818
Total other long term assets, net	39,841	35,051
Accrued liabilities:
Advance payments from customers	7,779	7,030
Rebates and lease buyouts	5,428	4,025
Group purchasing organization fees	3,449	3,737
Taxes payable	9,183	4,003
Other accrued liabilities	9,854	12,400
Total accrued liabilities	$ 35,693	$ 31,195

Balance Sheet Components - Accu

Balance Sheet Components - Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Stockholders' Equity, Beginning of period	$ 431,607	$ 402,388	$ 390,098
Other comprehensive income (loss) before reclassifications	4,219	(6,649)
Amounts reclassified from other comprehensive income (loss)	(813)	(140)
Other comprehensive gain (loss)	3,406	(6,789)	(1,369)
Stockholders' Equity, End of period	517,199	431,607	402,388
Foreign currency translation adjustments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Stockholders' Equity, Beginning of period	(10,764)	(2,730)
Other comprehensive income (loss) before reclassifications	3,810	(8,034)
Amounts reclassified from other comprehensive income (loss)	0	0
Other comprehensive gain (loss)	3,810	(8,034)
Stockholders' Equity, End of period	(6,954)	(10,764)	(2,730)
Unrealized gain (loss) on interest rate swap hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Stockholders' Equity, Beginning of period	1,245	0
Other comprehensive income (loss) before reclassifications	409	1,385
Amounts reclassified from other comprehensive income (loss)	(813)	(140)
Other comprehensive gain (loss)	(404)	1,245
Stockholders' Equity, End of period	841	1,245	0
Accumulated Other Comprehensive Income (Loss)
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Stockholders' Equity, Beginning of period	(9,519)	(2,730)	(1,361)
Other comprehensive gain (loss)	3,406	(6,789)	(1,369)
Stockholders' Equity, End of period	$ (6,113)	$ (9,519)	$ (2,730)

Net Investment in Sales-Type 51

Net Investment in Sales-Type Leases - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Capital Leased Assets [Line Items]
Collective allowance for credit losses	$ 0.2	$ 0.3
Minimum
Capital Leased Assets [Line Items]
Terms of sales-type leases (generally up to five years in length)	1 year
Maximum
Capital Leased Assets [Line Items]
Terms of sales-type leases (generally up to five years in length)	5 years

Net Investment in Sales-Type 52

Net Investment in Sales-Type Leases - Long Term Net Investment in Sales Type Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Leases [Abstract]
Net minimum lease payments to be received	$ 25,899	$ 33,591
Less: unearned interest income portion	(1,695)	(2,763)
Net investment in sales-type leases	24,204	30,828
Less: short-term portion	(8,769)	(10,243)
Long-term investment in sales-type leases, net	$ 15,435	$ 20,585

Net Investment in Sales-Type 53

Net Investment in Sales-Type Leases - Capital Leases, Future Minimum Payments Receivable (Details) $ in Thousands	Dec. 31, 2017USD ($)
Leases [Abstract]
2,018	$ 8,769
2,019	6,708
2,020	4,772
2,021	2,992
2,022	2,265
Thereafter	393
Total	$ 25,899

Goodwill and Intangible Asset54

Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Goodwill [Roll Forward]
Beginning balance	$ 327,724	$ 147,906
Additions	6,513	184,431
Adjustments	3,514	(4,613)
Ending balance	337,751	327,724
Automation and Analytics
Goodwill [Roll Forward]
Beginning balance	215,082	54,316
Additions	3,113	163,599
Adjustments	2,656	(2,833)
Ending balance	220,851	215,082
Medication Adherence
Goodwill [Roll Forward]
Beginning balance	112,642	93,590
Additions	3,400	20,832
Adjustments	858	(1,780)
Ending balance	116,900	$ 112,642
Accounts Receivable | Medication Adherence
Goodwill [Roll Forward]
Goodwill, purchase accounting adjustments	100
Other Noncurrent Assets | Medication Adherence
Goodwill [Roll Forward]
Goodwill, purchase accounting adjustments	700
Other Liabilities | Medication Adherence
Goodwill [Roll Forward]
Goodwill, purchase accounting adjustments	$ 2,600

Goodwill and Intangible Asset55

Goodwill and Intangible Assets - Intangible Assets, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Acquired Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	$ (80,030)	$ (54,059)
Foreign currency exchange rate fluctuations	107	(786)
Net carrying amount	168,107	190,283
Total intangible assets, net, gross carrying amount	248,030	245,128
Total intangible assets, net, net carrying amount	$ 168,107	190,283
Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	1 year
Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	30 years
Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 133,913	133,358
Accumulated amortization	(33,526)	(20,930)
Foreign currency exchange rate fluctuations	65	(596)
Net carrying amount	$ 100,452	$ 111,832
Customer relationships | Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	1 year	1 year
Customer relationships | Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	30 years	30 years
Acquired technology
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 74,593	$ 73,599
Accumulated amortization	(21,523)	(13,287)
Foreign currency exchange rate fluctuations	34	(159)
Net carrying amount	$ 53,104	$ 60,153
Acquired technology | Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	3 years	3 years
Acquired technology | Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	20 years	20 years
Backlog
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 21,712	$ 20,550
Accumulated amortization	(17,544)	(14,083)
Foreign currency exchange rate fluctuations	0	0
Net carrying amount	$ 4,168	$ 6,467
Backlog | Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	1 year	1 year
Backlog | Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	4 years	3 years
Trade name
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 8,716	$ 8,667
Accumulated amortization	(4,719)	(3,887)
Foreign currency exchange rate fluctuations	6	(31)
Net carrying amount	$ 4,003	$ 4,749
Trade name | Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	1 year	1 year
Trade name | Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	12 years	12 years
Patents
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 3,296	$ 3,154
Accumulated amortization	(1,418)	(1,264)
Foreign currency exchange rate fluctuations	2	0
Net carrying amount	$ 1,880	$ 1,890
Patents | Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	2 years	2 years
Patents | Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	20 years	20 years
Non-compete
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 1,900	$ 1,900
Accumulated amortization	(1,300)	(608)
Foreign currency exchange rate fluctuations	0	0
Net carrying amount	$ 600	$ 1,292
Useful life (in years)	3 years	3 years
In process technology
Acquired Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	$ 0	$ 0
Foreign currency exchange rate fluctuations	0	0
Carrying amount	$ 3,900	$ 3,900

Goodwill and Intangible Asset56

Goodwill and Intangible Assets - Future Amortization Expense for Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 25,600	$ 36,100	$ 6,900
2,018	23,433
2,019	17,953
2,020	16,739
2,021	15,439
2,022	13,973
Thereafter (excluding in-process technology)	76,670
Total intangibles assets, net carrying amount	$ 164,207

Debt and Credit Agreements - 20

Debt and Credit Agreements - 2016 Senior Secured Credit Facility (Details) - USD ($)	Apr. 03, 2017	Dec. 02, 2016	Jan. 05, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2017	Apr. 11, 2017	Jan. 06, 2016
Debt Instrument [Line Items]
Interest expense				$ 6,300,000	$ 5,300,000	$ 0
Wells Fargo Bank, National Association
Debt Instrument [Line Items]
Proceeds from debt				59,000,000
Repayment of debt and revolving credit facility				102,500,000			$ 137,000,000
Debt issuance cost, Amended Credit Agreement				2,106,000
Total Debt, net of deferred issuance cost				210,125,000	254,141,000		210,125,000
Carrying amount of debt				217,000,000	260,500,000		217,000,000
Long-term debt, fair value				220,900,000			220,900,000
Secured Credit Facility | Wells Fargo Bank, National Association | Line of Credit
Debt Instrument [Line Items]
Revolving credit facility			$ 400,000,000
Annual capital expenditure limitation per Credit Agreement			35,000,000					$ 45,000,000
Maximum allowed non-permitted investments per Credit Agreement			$ 10,000,000					$ 20,000,000
Debt issuance cost				$ 10,100,000			10,100,000
Secured Credit Facility | Wells Fargo Bank, National Association | Line of Credit | Interest Rate Option One | LIBOR | Minimum
Debt Instrument [Line Items]
Amounts draw under the Credit Agreements bears interest rate			1.50%
Secured Credit Facility | Wells Fargo Bank, National Association | Line of Credit | Interest Rate Option One | LIBOR | Maximum
Debt Instrument [Line Items]
Amounts draw under the Credit Agreements bears interest rate			2.25%
Secured Credit Facility | Wells Fargo Bank, National Association | Line of Credit | Interest Rate Option Two | LIBOR | Minimum
Debt Instrument [Line Items]
Amounts draw under the Credit Agreements bears interest rate			0.50%
Secured Credit Facility | Wells Fargo Bank, National Association | Line of Credit | Interest Rate Option Two | LIBOR | Maximum
Debt Instrument [Line Items]
Amounts draw under the Credit Agreements bears interest rate			1.25%
Secured Credit Facility | Wells Fargo Bank, National Association | Line of Credit | Interest Rate Option Two | Federal Funds
Debt Instrument [Line Items]
Amounts draw under the Credit Agreements bears interest rate			0.50%
Revolving Credit Facility
Debt Instrument [Line Items]
Debt instrument, term (in years)				5 years
Revolving Credit Facility | Wells Fargo Bank, National Association
Debt Instrument [Line Items]
Proceeds from debt				$ 59,000,000
Repayment of debt and revolving credit facility				92,500,000
Carrying amount of debt				$ 34,500,000	68,000,000		34,500,000
Revolving Credit Facility | Wells Fargo Bank, National Association | Line of Credit
Debt Instrument [Line Items]
Revolving credit facility			$ 200,000,000						$ 315,000,000
Debt instrument, term (in years)			5 years
Proceeds from debt	$ 59,000,000		$ 55,000,000
Revolving Credit Facility | Wells Fargo Bank, National Association | Line of Credit | Minimum
Debt Instrument [Line Items]
Commitment fee percentage, unused capacity			0.20%
Revolving Credit Facility | Wells Fargo Bank, National Association | Line of Credit | Maximum
Debt Instrument [Line Items]
Commitment fee percentage, unused capacity			0.35%
Term Loan Facility
Debt Instrument [Line Items]
Debt instrument, term (in years)				5 years
Term Loan Facility | Wells Fargo Bank, National Association
Debt Instrument [Line Items]
Proceeds from debt				$ 0
Repayment of debt and revolving credit facility				10,000,000
Carrying amount of debt				$ 182,500,000	$ 192,500,000		$ 182,500,000
Term Loan Facility | Wells Fargo Bank, National Association | Line of Credit
Debt Instrument [Line Items]
Revolving credit facility			$ 200,000,000
Debt instrument, term (in years)			5 years
Periodic payment, principal percent years one and two			5.00%
Periodic payment, principal percent years three and four			10.00%
Periodic payment, principal percent year five			15.00%
Proceeds from debt		$ 40,000,000	$ 200,000,000
Letter of Credit | Wells Fargo Bank, National Association
Debt Instrument [Line Items]
Revolving credit facility			$ 10,000,000
Letter of Credit | Wells Fargo Bank, National Association | Line of Credit | Minimum
Debt Instrument [Line Items]
Commitment fee percentage			1.50%
Letter of Credit | Wells Fargo Bank, National Association | Line of Credit | Maximum
Debt Instrument [Line Items]
Commitment fee percentage			2.25%
Bridge Loan [Member] | Wells Fargo Bank, National Association
Debt Instrument [Line Items]
Revolving credit facility			$ 10,000,000

Debt and Credit Agreements - Sc

Debt and Credit Agreements - Schedule of Debt Obligations (Details) - USD ($) $ in Thousands	12 Months Ended			24 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2017
Components of beginning debt balance [Abstract]
Long term debt, current portion, net of deferred issuance cost at beginning of period	$ 8,410
Long-term debt, current portion, net	245,731
Debt Borrowing, Repayment, Amortization during period [Abstract]
Amortization of debt financing fees	1,590	$ 1,590	$ 0
Components of ending debt balance [Abstract]
Long term debt, current portion, net of deferred issuance cost at beginning of period	15,208	8,410		$ 15,208
Long-term debt, current portion, net	194,917	245,731		194,917
Wells Fargo Bank, National Association
Components of beginning debt balance [Abstract]
Debt under credit facilities at beginning of period	260,500
Deferred issuance cost, net at beginning of period	(6,359)
Total Debt, net of deferred issuance cost at beginning of period	254,141
Long term debt, current portion, net of deferred issuance cost at beginning of period	8,410
Long-term debt, current portion, net	245,731
Debt Borrowing, Repayment, Amortization during period [Abstract]
Proceeds from debt	59,000
Debt issuance cost	(2,106)
Increase in borrowings net of deferred issuance cost	56,894
Repayment of debt and revolving credit facility	(102,500)			(137,000)
Amortization of debt financing fees	1,590
Decrease in repayment/amortization net of deferred issuance cost	(100,910)
Components of ending debt balance [Abstract]
Debt under credit facilities at ending of period	217,000	260,500		217,000
Deferred issuance cost, net at ending of period	(6,875)	(6,359)		(6,875)
Total Debt, net of deferred issuance cost at ending of period	210,125	254,141		210,125
Long term debt, current portion, net of deferred issuance cost at beginning of period	15,208	8,410		15,208
Long-term debt, current portion, net	194,917	245,731		194,917
Term Loan Facility | Wells Fargo Bank, National Association
Components of beginning debt balance [Abstract]
Debt under credit facilities at beginning of period	192,500
Debt Borrowing, Repayment, Amortization during period [Abstract]
Proceeds from debt	0
Repayment of debt and revolving credit facility	(10,000)
Components of ending debt balance [Abstract]
Debt under credit facilities at ending of period	182,500	192,500		182,500
Revolving Credit Facility | Wells Fargo Bank, National Association
Components of beginning debt balance [Abstract]
Debt under credit facilities at beginning of period	68,000
Debt Borrowing, Repayment, Amortization during period [Abstract]
Proceeds from debt	59,000
Repayment of debt and revolving credit facility	(92,500)
Components of ending debt balance [Abstract]
Debt under credit facilities at ending of period	$ 34,500	$ 68,000		$ 34,500

Debt and Credit Agreements - 59

Debt and Credit Agreements - 2013 Credit Agreement (Details) - Wells Fargo Bank, National Association - USD ($)	Jan. 06, 2016	Jan. 05, 2016
Letter of Credit
Debt Instrument [Line Items]
Revolving credit facility with a letter of credit sub limit		$ 10,000,000
Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Revolving credit facility with a letter of credit sub limit	$ 315,000,000	$ 200,000,000

Deferred Revenue (Details)

Deferred Revenue (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred Revenue Disclosure [Abstract]
Short-term deferred revenue	$ 86,100	$ 87,500
Deferred service revenue, cost of sales, current	16,900	14,200
Long-term deferred revenue	$ 17,244	$ 17,051

Commitments and Contingencies61

Commitments and Contingencies (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Rent expense	$ 11,500	$ 9,800	$ 7,000
2,018	12,167
2,019	11,945
2,020	10,755
2,021	10,471
2,022	8,776
Thereafter	26,243
Total minimum future lease payments	80,357
Purchase obligation due in the next twelve months	$ 58,100
Standard product warrant, duration following installation	30 days
Medication packaging system duration of limited warranties	6 months

Employee Benefits and Share-B62

Employee Benefits and Share-Based Compensation - Stock Purchase Plan (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	7,835
1997 Employee Stock Purchase Plan | Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum percentage of earnings allowed for purchase of shares	15.00%
Maximum fair market value of shares | $	$ 25,000
Purchase price of common stock, percent	85.00%
Shares reserved for future issuance (in shares)	2,365

Employee Benefits and Share-B63

Employee Benefits and Share-Based Compensation - Stock Award Plans (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2017shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	7,835
2009 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	5,500
2009 Plan | Vesting one year from the vesting commencement date
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of award vesting	25.00%
2009 Plan | Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)	4 years
Shares reserved for future issuance (in shares)	3,323
2009 Plan | Employee Stock Option | Vesting one year from the vesting commencement date
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)	1 year
2009 Plan | Employee Stock Option | Vesting in equal monthly installments
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Monthly vesting installments	36 months

Employee Benefits and Share-B64

Employee Benefits and Share-Based Compensation - Shared-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	$ 21,857	$ 19,500	$ 14,921
Cost of product and service revenues
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	3,478	2,596	2,111
Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	3,590	3,128	2,060
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	14,789	13,776	10,750
2009 Plan
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Income tax benefit	$ 8,200	$ 5,400	$ 5,000

Employee Benefits and Share-B65

Employee Benefits and Share-Based Compensation - Valuation of Share Based Awards (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.90%	1.50%	1.70%
Dividend yield	0.00%	0.00%	0.00%
Expected volatility	29.60%	30.60%	32.00%
Expected life (in years)	4 years 8 months 1 day	4 years 10 months 24 days	5 years
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility, minimum	25.80%	25.80%	25.70%
Expected volatility, maximum	32.80%	34.80%	37.50%
ESPP Risk-free interest rate, minimum	0.52%	0.34%	0.03%
ESPP Risk-free interest rate, maximum	1.39%	0.79%	0.79%
Employee Stock | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)	6 months	6 months	6 months
Employee Stock | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)	2 years	2 years	2 years
1997 Employee Stock Purchase Plan | Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%	0.00%

Employee Benefits and Share-B66

Employee Benefits and Share-Based Compensation - Stock Options and ESPP Shares (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
2009 Plan
Number of Shares
Outstanding at December 31, 2016 (in shares)	3,214
Granted (Awarded) (in shares)	1,045
Exercised (Released) (in shares)	(813)
Expired (in shares)	(6)
Forfeited (in shares)	(117)
Outstanding at December 31, 2017 (in shares)	3,323	3,214
Exercisable at December 31, 2017 (in shares)	1,350
Vested and expected to vest at December 31, 2017 and thereafter (in shares)	3,323
Weighted-Average Exercise Price
Outstanding at December 31, 2016 (in dollars per share)	$ 26.06
Granted (Awarded) (in dollars per share)	45.13
Exercised (Released) (in dollars per share)	22.28
Expired (in dollars per share)	27.54
Forfeited (in dollars per share)	33.39
Outstanding at December 31, 2017 (in dollars per share)	32.72	$ 26.06
Exercisable at December 31, 2017 (in dollars per share)	23.87
Vested and expected to vest at December 31, 2017 and thereafter (in dollars per share)	$ 32.72
Weighted-Average Remaining Years	7 years 7 months 13 days	7 years 3 months
Exercisable at December 31, 2017 (in years)	5 years 9 months 26 days
Vested and expected to vest at December 31, 2017 and thereafter (in years)	7 years 7 months 13 days
Outstanding at December 31, 2017, Aggregate Intrinsic Value	$ 53,953	$ 26,331
Exercisable at December 31, 2017, Aggregate Intrinsic Value	33,293
Vested and expected to vest at December 31, 2017 and thereafter, Aggregate Intrinsic Value	$ 53,953
2009 Plan | Employee Stock Option
Weighted-Average Exercise Price
Weighted-average fair value (in usd per share)	$ 13.25	$ 9.33	$ 9.67
Intrinsic value of options exercised	$ 18,200	$ 5,600	$ 11,300
Unrecognized compensation cost of unvested stock options	$ 18,900	$ 13,300
Weighted average period of compensation cost recognized (in years)	2 years 11 months 9 days	3 years
1997 Employee Stock Purchase Plan | Employee Stock
Weighted-Average Exercise Price
Weighted average period of compensation cost recognized (in years)	1 year 4 months 6 days
Shares purchased under ESPP	500
Shares issued under ESPP	6,000
Unrecognized compensation cost	$ 900

Employee Benefits and Share-B67

Employee Benefits and Share-Based Compensation - Restricted Stock Units and Restricted Stock Awards (Details) - 2009 Plan - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Restricted Stock Units (RSUs)
Number of Shares
Nonvested, beginning balance (in shares)	505
Granted (Awarded) (in shares)	245
Vested (Released) (in shares)	(215)
Forfeited (in shares)	(34)
Nonvested, ending balance (in shares)	501	505
Weighted-Average Grant Date Fair Value
Nonvested, beginning balance (in dollars per share)	$ 31.42
Granted (Awarded) (in dollars per share)	45.97	$ 32.58	$ 31.44
Vested (Released) (in dollars per share)	30.41
Forfeited (in dollars per share)	32.39
Nonvested, ending balance (in dollars per share)	$ 38.90	$ 31.42
Weighted-Average Remaining Years	1 year 6 months	1 year 7 months 5 days
Aggregate Intrinsic Value
Non-vested at December 31, 2017	$ 24,293	$ 17,135
Fair value of restricted stock units	6,500	4,800	$ 4,700
Unrecognized compensation cost	$ 16,100	$ 12,800
Weighted average period of compensation cost recognized (in years)	2 years 8 months 27 days	2 years 10 months 15 days
Restricted Stock
Number of Shares
Nonvested, beginning balance (in shares)	30
Granted (Awarded) (in shares)	23
Vested (Released) (in shares)	(30)
Nonvested, ending balance (in shares)	23	30
Weighted-Average Grant Date Fair Value
Nonvested, beginning balance (in dollars per share)	$ 31.57
Granted (Awarded) (in dollars per share)	41.10	$ 31.59	$ 36.05
Vested (Released) (in dollars per share)	31.58
Nonvested, ending balance (in dollars per share)	$ 41.07	$ 31.57
Aggregate Intrinsic Value
Fair value of restricted stock units	$ 1,000	$ 1,200	$ 1,100
Unrecognized compensation cost	$ 300	$ 400
Weighted average period of compensation cost recognized (in years)	4 months 21 days	4 months 15 days

Employee Benefits and Share-B68

Employee Benefits and Share-Based Compensation - Performance-based Restricted Stock Units Activity (Details) - Performance Shares - USD ($) $ / shares in Units, $ in Millions	Mar. 07, 2017	Feb. 08, 2017	Mar. 07, 2016	Feb. 04, 2016	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Weighted-Average Grant Date Fair Value
Trading days		20 days		20 days	20 days
2009 Plan
Number of Shares
Nonvested, beginning balance (in shares)						184,000
Granted (Awarded) (in shares)						148,000
Vested (Released) (in shares)						(107,000)
Nonvested, ending balance (in shares)						225,000	184,000
Weighted-Average Grant Date Fair Value
Nonvested, beginning balance (in dollars per share)						$ 24.89
Granted (Awarded) (in dollars per share)						34.05	$ 24.66	$ 29.56
Vested (Released) (in dollars per share)						24.36
Nonvested, ending balance (in dollars per share)						$ 31.18	$ 24.89
Weighted average period of compensation cost recognized (in years)						1 year 2 months 23 days
Unrecognized compensation cost						$ 2.7	$ 1.6
Vested in period, fair value						$ 2.6	$ 2	$ 1.9
2015 Performance Based Restricted Stock Units
Number of Shares
Awards eligible for vesting (in shares)			60,000
Awards vested by period end (in shares)						45,000
Weighted-Average Grant Date Fair Value
Percentile rank of stockholder return			66.00%
Percentage of shares eligible for time-based vesting			100.00%
Percentage of award vesting			25.00%
Vesting period (in years)						3 years
2016 Performance Based Restricted Stock Units
Number of Shares
Awards eligible for vesting (in shares)	122,740
Awards vested by period end (in shares)						61,375
Weighted-Average Grant Date Fair Value
Percentile rank of stockholder return	71.50%
Percentage of shares eligible for time-based vesting	100.00%
Percentage of award vesting	25.00%
Vesting period (in years)						36 months
Officer
Number of Shares
Granted (Awarded) (in shares)						147,830	122,740

Employee Benefits and Share-B69

Employee Benefits and Share-Based Compensation - Summary of Shares Reserved for Future Issuance Under Equity Incentive Plans (Details) shares in Thousands	Dec. 31, 2017shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for future issuance	7,835
1997 Employee Stock Purchase Plan | ESPP shares available for future issuance
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for future issuance	2,365
2009 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for future issuance	5,500
2009 Plan | Share options outstanding
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for future issuance	3,323
2009 Plan | Non-vested restricted stock awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for future issuance	749
2009 Plan | Shares authorized for future issuance
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for future issuance	1,398

Employee Benefits and Share-B70

Employee Benefits and Share-Based Compensation - 401(k) Plan (Details) - Other Postretirement Benefit Plan - Omnicell Plan - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Defined Contribution Plan Disclosure [Line Items]
Employer matching contribution, percent of employee contribution	50.00%
Maximum amount of employer contribution	$ 2,500
401(k) contributions	$ 3,800,000	$ 1,900,000	$ 1,800,000

Stock Repurchases - Additional

Stock Repurchases - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Aug. 02, 2016
Equity, Class of Treasury Stock [Line Items]
Total number of shares repurchased	0	0
Stock repurchases			$ 50,021,000
August 2012 Stock Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Stock repurchases program, authorized amount				$ 50,000,000
2016 and 2014 Share Repurchase Programs
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, remaining authorized repurchase amount	$ 54,900,000

Equity Offerings (Details)

Equity Offerings (Details) - Distribution Agreement - USD ($)	Nov. 03, 2017	Dec. 31, 2017
Subsidiary, Sale of Stock [Line Items]
Maximum aggregate offering price	$ 125,000,000
Gross proceeds from sales of common stock		$ 14,700,000
Issuance costs on sales of common stock		$ 800,000
Number of shares sold		294,000
Price per share (in dollars per share)		$ 49.85

Segment and Geographical Info73

Segment and Geographical Information - Financial Performance of Reporting Segments (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)segment	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Segment Reporting Information [Line Items]
Number of segments | segment	2
Number of reportable segments | segment	2
Revenues	$ 716,165	$ 692,623	$ 484,559
Cost of revenues	394,077	378,823	236,629
Gross profit	322,088	313,800	247,930
Operating expenses	316,334	307,319	199,298
Income from operations	5,754	6,481	48,632
Operating Segments
Segment Reporting Information [Line Items]
Revenues	716,165	692,623	484,559
Cost of revenues	394,077	378,823	236,629
Gross profit	322,088	313,800	247,930
Operating expenses	235,435	223,354	138,342
Income from operations	86,653	90,446	109,588
Operating Segments | Automation and Analytics
Segment Reporting Information [Line Items]
Revenues	590,392	593,626	390,321
Cost of revenues	308,443	310,967	171,943
Gross profit	281,949	282,659	218,378
Operating expenses	193,700	198,511	114,084
Income from operations	88,249	84,148	104,294
Operating Segments | Medication Adherence
Segment Reporting Information [Line Items]
Revenues	125,773	98,997	94,238
Cost of revenues	85,634	67,856	64,686
Gross profit	40,139	31,141	29,552
Operating expenses	41,735	24,843	24,258
Income from operations	(1,596)	6,298	5,294
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Operating expenses	$ 80,899	$ 83,965	$ 60,956

Segment and Geographical Info74

Segment and Geographical Information - Significant Customers (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Customer Concentration Risk
Segment Reporting Information [Line Items]
Concentration risk percentage	51.20%	51.20%	65.20%

Segment and Geographical Info75

Segment and Geographical Information - Geographical Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 716,165	$ 692,623	$ 484,559
Total property and equipment, net	42,595	42,011	32,309
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	617,268	591,566	403,375
Total property and equipment, net	34,899	36,497	29,506
Non-US
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	98,897	101,057	81,184
Total property and equipment, net	$ 7,696	$ 5,514	$ 2,803

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Domestic	$ 19,889	$ 1,471	$ 51,089
Foreign	(20,768)	(3,419)	(4,845)
Income (loss) before provision for income taxes	$ (879)	$ (1,948)	$ 46,244

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Current:
Federal	$ 2,430	$ 6,724	$ 13,840
State	1,852	1,323	2,475
Foreign	745	46	203
Total current income taxes	5,027	8,093	16,518
Deferred:
Federal	(16,118)	(3,378)	846
State	(2,612)	(1,802)	(379)
Foreign	(7,781)	(5,464)	(1,501)
Total deferred income taxes	(26,511)	(10,644)	(1,034)
Total provision for (benefit from) income taxes	$ (21,484)	$ (2,551)	$ 15,484

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
U.S. federal tax provision at statutory rate	$ (308)	$ (682)	$ 16,181
State taxes	19	(311)	1,365
Non-deductible expenses	1,373	1,212	551
Acquisition costs	0	845	239
Share-based compensation expense	39	1,941	748
Research tax credits	(3,233)	(2,075)	(1,324)
Domestic production deduction	(621)	(890)	(1,133)
Gain on investment	0	0	(1,205)
Tax audit settlement	0	(2,499)	0
Foreign rate differential	938	(154)	123
Stock option tax benefit	(5,926)	0	0
One-time Impact of the Tax Act	(13,391)	0	0
Other	(374)	62	(61)
Total provision for (benefit from) income taxes	$ (21,484)	$ (2,551)	$ 15,484

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets (liabilities):
Deferred revenue	$ 6,345,000	$ 5,857,000
Stock compensation	4,460,000	6,451,000
Inventory related items	2,441,000	2,915,000
Tax credit carry forwards	9,349,000	4,871,000
Reserves and accruals	3,960,000	4,675,000
Loss carry forwards	8,643,000	8,077,000
Other, net	1,307,000	847,000
Total net deferred tax assets	36,505,000	33,693,000
Intangibles	(36,780,000)	(57,427,000)
Depreciation and amortization	(14,338,000)	(20,071,000)
Prepaid expenses	(4,512,000)	(3,746,000)
Total deferred tax liabilities	(55,630,000)	(81,244,000)
Net deferred tax liabilities	(19,125,000)	$ (47,551,000)
Valuation allowance	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Tax Credit Carryforward [Line Items]
One-time tax benefit	$ 13,400,000
Valuation allowance	0
Unrecognized tax benefits that would impact tax expense	10,700,000
Uncertain tax positions, interest and penalties	300,000	$ 500,000	$ 100,000
Interest and penalties accrued	1,400,000	$ 1,100,000	$ 600,000
Internal Revenue Service (IRS)
Tax Credit Carryforward [Line Items]
Net operating loss	6,600,000
State and Local Jurisdiction
Tax Credit Carryforward [Line Items]
Net operating loss	6,100,000
Research Tax Credit Carryforward | Internal Revenue Service (IRS)
Tax Credit Carryforward [Line Items]
Tax credit carryforward amount	2,400,000
Research Tax Credit Carryforward | State and Local Jurisdiction
Tax Credit Carryforward [Line Items]
Tax credit carryforward amount	$ 8,800,000

Income Taxes - Schedule of Unre

Income Taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2017
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning of the Period Balance	$ 11,616	$ 9,150	$ 8,485
Increases related to tax positions taken during a prior period	503	244	37
Decreases related to tax positions taken during the prior period	(1,782)	(1,980)	(895)
Increases related to tax positions taken during the current period	805	6,724	1,807
Decreases related to settlements	0	(2,178)	0
Decreases related to expiration of statute of limitations	(401)	(344)	(284)
End of the Period Balance	$ 11,616	$ 9,150	$ 8,485	$ 10,741

Restructuring Expenses (Details

Restructuring Expenses (Details) $ in Millions	Feb. 15, 2017Employee	Jun. 30, 2016Employee	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)
Restructuring Cost and Reserve [Line Items]
Number of positions eliminated | Employee	100	36
Restructuring payments				$ 1.7
Restructuring expenses				$ 1.7
Employee severance
Restructuring Cost and Reserve [Line Items]
Restructuring payments			$ 3.7
Facility closing
Restructuring Cost and Reserve [Line Items]
Facility-related costs incurred			4.2
Restructuring payments			0.6
Accrued compensation | Facility closing
Restructuring Cost and Reserve [Line Items]
Restructuring reserve, current			$ 0.4

Schedule II Valuation and Qua83

Schedule II Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	$ 5,050	$ 1,409	$ 1,368
Charged to Cost and Expenses	946	812	354
Credited to Other Accounts	3	77	134
Amount Written Off	(402)	(369)	(447)
Acquisition and translation adjustments	333	3,121	0
Balance at End of Period	5,930	5,050	1,409
Accounts Receivable
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	4,796	1,240	1,206
Charged to Cost and Expenses	1,008	727	453
Credited to Other Accounts	3	77	28
Amount Written Off	(402)	(369)	(447)
Acquisition and translation adjustments	333	3,121	0
Balance at End of Period	5,738	4,796	1,240
Investment in sales-type leases
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	254	169	162
Charged to Cost and Expenses	(62)	85	(99)
Credited to Other Accounts	0	0	106
Amount Written Off	0	0	0
Acquisition and translation adjustments	0	0	0
Balance at End of Period	$ 192	$ 254	$ 169